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Zusammenfassung 
 
Veränderungen im Methylierungsmuster der DNA geschehen früh in der Entwicklung von 
Tumoren. Zumeist sind Promoter-Regionen von Tumorsupressor-Genen und Onko-Genen 
betroffen, die einen Wachstumsvorteil der Krebszellen zur Folge haben. In dieser Studie 
wurde die Möglichkeit der Detektion dieser epigenetischen Aberrationen in zellfreier DNA 
aus Serum von Brustkrebspatienten untersucht, da diese potenzielle Biomarker zur minimal-
invasiven Diagnostik darstellen. 
Hierzu wurden unterschiedliche DNA–Isolationsverfahren und Amplifikationsmethoden zur 
Anreicherung methylierter DNA getestet. Mit den optimierten Methoden wurde Serum-DNA 
von Brustkrebspatienten mit A) malignen Neoplasmen (n=40), B) nicht invasiv wachsenden 
Tumoren (n=18) und C) gesunden Kontrollprobandinnen (n=24) isoliert.  
Der DNA Gehalt im Serum von Brustkrebspatienten  mit metastasierenden Tumoren 
[45,64ng/ml ± 32,31ng]  war gegenüber gesunden Probanden [10,58ng/ml ± 9,71ng] 
signifikant erhöht (p = 0,0013; Wilcoxon-Rangsummentest). 
Die methylierte DNA Fraktion der Proben wurde mit einem Restriktionsenzymen – basierten 
Verfahren und einer „Rolling Circle Amplifikation“ (RCA) genomweit angereichert. Nach 
erfolgreicher Prozessierung  von 72 der 82 DNA Proben konnte ein Biomarker-Screening  zur 
Unterscheidung der Patientengruppen durchgeführt werden. Dazu wurden 360 ausgewählte 
DNA Bereiche in Multiplex-PCR Reaktionen amplifiziert und die PCR-Produkte durch 
Hybridisierung auf einem „targeted-micro-array“ detektiert. Die Micro-Array Analyse 
erlaubte eine Unterscheidung zwischen den Brustkrebspatienten und den Normal Kontrollen, 
wobei jedoch nach kritischer Betrachtung ein experimenteller Bias welcher zu diesen 
Unterschieden beiträgt nicht ausgeschlossen werden kann. 
In dieser Arbeit konnte somit ein Protokoll erarbeitet werden, das ein genomweites 
Biomarker-Screening zur Auffindung von DNA-Methylierungsmarkern für die minimal 
invasive Diagnostik aus geringsten Mengen zellfreier Serum DNA ermöglicht.  
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Abstract: 
 
Changes in DNA-methylation patterns are an early event in cancer development. Many 
promoter regions of tumor suppressor genes or oncogenes change their methylation status due 
to growth advantages of the cancer cell. During this study we investigated detection of these 
epigenetic aberrations in cell free DNA derived from serum of breast cancer patients, for 
elucidation of potential biomarkers for minimal invasive diagnostics. 
Therefore several DNA isolation approaches and genome wide amplification methods for 
enrichment of methylated DNA were tested. Applying these optimized methods serum-DNA 
was isolated form sera of A) breast cancer patients with malign neoplasm (n=40), B) sera of 
patients with a non-invasive cancer phenotype (n= 18) and C) healthy normal controls (n=24). 
The DNA concentrations in serum of patients with a metastasizing tumor (45,64 ng/ml +/- 
32,31ng) was significantly increased when compared to serum-concentrations of normal 
controls (10,58ng/ml +/- 9,71ng),  (p = 0.0013, Wilcoxon-test). 
The methylated fraction of the sample DNA was genome wide enriched, using a restriction 
enzyme based approach combined with a subsequent “Rolling Circle Amplification” (RCA). 
After successful sample preparation of 72 out of 82 DNA samples, a biomarker screening to 
distinguish between the patient study groups was performed. Therefore 360 selected DNA 
sequences were amplified within a multiplex-PCR approach and amplicons detected upon 
hybridization onto a target micro-array. Micro-array analyses enabled identification of 
marker-candidates for classification of study groups. However upon critical examination of 
our experimental setup, we cannot exclude that some experimental bias contributes to this 
discrimination. 
In this work a protocol was established which enables a genome wide biomarker screening for 
elucidation of DNA methylation markers for minimal invasive diagnostic testing using 
spurious amounts of cell free serum DNA. 
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1. Introduction 
 
1.1 Epigenetics and DNA Methylation 
 
1.1.1 Preface 
 
The term “epigenetics” describes the existence of inheritable factors that contribute to the 
phenotype of an individual, which are not determined in the DNA sequence. Two mechanisms 
are available to induce a modification of a cytosine base by addition of a methyl residue. The 
DNA can be methylated de novo, or an existing methylation pattern is maintained during 
DNA replication by the DNA maintenance methylase. In this case the methylation pattern of 
the parental DNA stand is transferred to the daughter strands during cell division, as the DNA 
maintenance methyltransferase modifies the daughter strand according to the methylation 
pattern of the parental DNA (Lewin et al., 2004).  
In most cases, DNA methylation goes along with gene silencing. This can occur via the 
influence of transcription factors or the formation of heterochromatin. Heterochromatin is the 
transcriptional inactive form of a DNA molecule and in this context another example for 
epigenetic regulation in eukaryotes. This chromatin form is packed more tightly than 
euchromatin and the histones in these regions are modified in a different way than the 
euchromatin. This tight packed organisation of nucleosoms occurs constitutively in centromer 
or telomere regions of chromosomes and throughout the inactive X-chromosome (Dimitri et 
al., 2009). 
Different acetylation and methylation patterns of the N-terminus of histones are key-
regulators of epigenetic regulation of gene-expression. This is named the „histone code“, 
which includes additional modifications, like phosphorylation or ubiquitination. Acetylation 
can lead to a more relaxed chromatin form or to the formation of histone remodelling 
complexes, which both can facilitate transcription.  
The concept of epigenetics includes many different procedures of gene-regulation, which are 
closely related (Figure 1), not only DNA methylation, investigated in this work, but also 
RNAi as well as histone modification play an important role in the understanding of the 
epigenetic influence on gene expression (Figure 1) (Egger et al., 2004). 
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Fig.1: Overview of interaction between epigenetic factors in heritable silencing. Adopted from (Egger et al., 
2004) 
 
 
1.1.2 DNA Methylation 
 
The modification of DNA on specific sites in the genome happens for different reasons. In 
bacteria DNA methylation is required to distinguish between the own bacterial DNA and 
foreign DNA. In this case, methylation serves as protection mechanism, as the endonucleases 
of the bacterium digest alien DNA (Knipers, 2001).  
Bacteria require this modification also for additional proof reading during DNA synthesis. For 
this mechanism it is necessary that the bacterium can recognize the parental DNA strand, 
which is methylated and correct the errors on the daughter strand, which gets methylated after 
this reaction. 
In eukaryotes, about 20% of the cytosines are methylated and the main known function is not 
as mentioned above host defence, but control of transcription. Typically the cytosine in CpG 
dinucleotides is methylated. mC is always methylated in both DNA strands symmetrically: 
 
 5´  mCpG      3´ 
 3´     GpCm   5´ 
 
A vast group of enzymes control DNA methylation in eukaryotic cells. Demethylases like 
MBD2, MBD4 or TDG (Ooi and Bestor, 2008) remove CH3 residues from the DNA and 
methylases like DNMT1, DNMT3a or DNTMT3b add methyl-groups to cytosines (Jair et al., 
2006). The methyltransferases can be divided into two groups, the maintenance methylases 
and the de novo methylases. The maintenance methylases recognize hemi-methylated sites, 
which arise from replication of the DNA. In this case one strand of the DNA is methylated 
(parental) and one strand is left unmodified. These enzymes work constitutively and convert 
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every hemi-methylated site into a fully methylated one with virtually 100% efficiency. This 
process ensures that the methylation pattern is held up after replication.  
In contrast to the maintenance methylation system, the de novo methylases act only on non-
methylated DNA, where they add a methyl-group on one strand. Generally spoken, if a 
promoter region gets methylated, the gene-expression is truncated via diverse epigenetic 
mechanisms or binding of repressive acting proteins (Gopalakrishnan et al., 2008). 
An important mechanism controlled by DNA methylation is genomic imprinting. This 
mechanism starts during gametogenesis. First, the existing methylation pattern is erased, 
followed by recreation of the methylation pattern during maturation of spermatocytes or 
oocytes. The methylation pattern of maternal and paternal gametes is different, but only a few 
regions of each genome are unmethylated at this stage of development (Butler, 2009). 
The second systematic alteration of the DNA methylation pattern takes place in early 
embryogenesis. At that time, some sites stay methylated, whereas de-methylation activates 
many genes. This process results in a specific pattern of methyl groups in germ line cells, 
which is on imprinted loci dependant on the inheritance of the alleles form either the mother 
or the father. 
Exceptionally we can find the hereditary information in the methylation pattern of the DNA 
and not in the DNA sequence, in other words one can distinguish between the parental origins 
of alleles whose sequence is identical by the differential methylation pattern. (Lewin, 2004) 
 
 
1.1.3 CpG islands 
 
CpG means Cytosine phosphatidyl Guanine. This term was introduced to distinguish easily 
between GC frequency and CG dinucleotides. The “p” refers to the phosphodiesterbond 
between every particular base in a DNA molecule. The CpG dinucleotides should statistically 
appear with a frequency of 4% in the DNA sequence, considering the G-C content of 41% in 
the human genome. Actually, the commonness of this dinucleotides is 0,8%, in other words 
only 20% of the expected frequency. The reason for this fact is found in the chemical 
instability of the base Cytosine, which can get converted into a thymidine by deamination due 
to diverse stress factors. (Knipers, 2001) 
Per definition, a CpG island contains a G-C content of minimum 55% over a length of 200bp 
in minimum (Egger et al., 2004). Using this standard, about 45000 CpG islands were found, 
but if CG rich sequences in Alu repeats are subtracted, about 29000 CpG islands remain. The 
typical CpG island is found around the 5´end of a gene. This G-C rich DNA stretch has a 
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length of 1kb to 2 kb most of them start in 5´region of the promoter and reach into the coding 
region of the gene. More precise estimations about the number of genes with a CpG island 
come to 70% of all genes in the human genome, but it should be mentioned that all 
housekeeping genes have a CpG island in their 5´region. This means that half of the CpG 
islands in the human genome are found in housekeeping genes, so they are unmethylated 
throughout, because these genes are constitutively expressed. The remaining CpG stretches 
are found in tissue-regulated genes, where their gene-expression is, among other things, also 
dependent on the methylation status of the CpG island in their promoter-region. In the end, 
less than 40% of non-constitutive expressed genes bear CpG islands (Lewin, 2004). 
DNA methylation can induce several courses in a cell. It may comparably cause the binding 
of repressors or enhancers dependant on the gene region. Further DNA methylation may 
silence gene-expression by preventing these factors from binding to the DNA. 
However, the current understanding of DNA methylation suggests that if a CpG island is 
methylated throughout, there is no gene-expression, whereas the unmethylated status of a 
CpG island is an indication for active gene-expression. In other words a hypo-methylated 
gene may be active (Figure 2), but the absence of methyl-groups is no evidence for the 
transcription of a particular gene. 
In every case, no universal prediction can be made about linkage between DNA methylation 
and gene-expression, because transcription also takes place if the CpG island is partially 
methylated. It seems that a few methyl residues at the core region of a gene are responsible 
for the silencing of a gene. Anyway, the general rule maintains that DNA methylation 
prevents genes from expression or at least is a strong indicator for a silenced gene. 
 
Fig. 2 The effect of the methylation pattern on gene-expression.  
This schematic drawing shows possible effects of methylation on 
gene-expression, observed at gene start region of a gene associated 
with aging chronic inflammation. Normal tissue samples of young 
individuals are unmethylated at this site. Open circles mark 
unmethylated CpGs; close circles mark methylated CpG islands; (a) 
promoter region is unmethylated; gene-expression can take place; 
(b) methylation in the 3´region of the promoter does not impair 
transcription; (c,d) core region is not methylated therefore the gene 
is still expressed. (d) Methylation pattern promotes further 
methylation and results in complete methylation of this site (e); 
(f) Only the core region is methylated, which leads to inactivation of 
the gene. adopted from: (Ushijima, 2005) 
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1.2 Breast cancer 
 
1.2.1 Cancer 
 
Hippocrates, who noticed a similarity between a breast abscess and the leg of a crab, 
introduced the term cancer. Later all superficially detectable abscesses, which infiltrated 
neighbouring tissues were called cancer. 
Individual somatic cells, which lose their ability to grow, divide and undergo apoptosis in a 
distinct span of time that is predetermined by the normal cell cycle, lead to an illness, called 
cancer or malignant neoplasm. Cancer cells have quasi lost their growth control and gained 
the ability to grow in inappropriate locations. In short, these are normal cells that get 
immortalized due to mutations or epigenetic events. 
The appearance of cancer can be understood as a multi-step process that results in an 
accumulation of mutations and genetic instability of the affected cells. The fundamental 
model assumes that the initiation of a tumor needs two or more alterations in the genome or 
epigenetic events of the affected cell, such as changes of methylation pattern or miRNA 
expression, followed by further changes that strengthen the tumorigenic state of the cancer 
cells (Knudson, Jr., 1971) 
One of the central dogmas in current understanding of cancer, is an increased mutation rate of 
cancer cells, which leads, on one hand to the accumulation of mutations mentioned above and, 
on the other hand, to an acceleration of clonal selection of tumor cells, because cells, which 
divide more aggressively will overgrow the remaining healthy ones. Therefore cancer 
progression can be seen as selection between and final survival of the fittest cancer cell, 
which results in an enhancement of cancerous properties of the cells and lastly a development, 
which invariably goes in the direction of the more malignant cell. (Lewin, 2004) 
In principle, tumors can be partitioned into benign neoplasms and malign neoplasms, whereat 
the benign tumor cells stop to proliferate by themselves (Ueng et al., 2009). Per definition, a 
benign tumor does not grow unlimited and does not invade neighbouring tissue or show any 
metastasizing characteristics. In other words, benign tumors sum up all abnormal tissue 
masses that cannot be classified as cancers. Although these benign neoplasms have the 
potential to become malignant, it happens very seldom and the benign tumors maintain their 
typical encapsulated shape, which mostly inhibits the creation of malignant characteristics. In 
most cases this neoplasm causes no health problems. 
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Malign neoplasms, also referred to as cancer or invasive tumor, are classified in different 
grades and stages. A pathologist defines the similarity between the surrounding tissue and the 
tumor tissue, which leads to a division in different grades of the cancer. This classification 
starts with G1; where tumor cells resemble normal cells and grow slow, whereby the malign 
neoplasm shows low aggressive behaviour. G4 is the highest grade, where cells do not look 
like normal cells anymore and the tumor grows and spreads fast. 
(http://www.cancertreatmentwatch.org/general/grading.shtml) 
The stage of the cancer is defined by the degree of the invasion of the cancer cells in the 
patients’ body. This overall stage grouping ranges from 0 to 4 often in roman numerals; here 
stage 0 is a carcinoma in situ. This neoplastic cells proliferate in their normal habitat and do 
not invade into neighbouring tissue, which may lead to a malign neoplasm if long enough 
untreated. As one can imagine stage IV is the worst development of the illness, where cancers 
often have metastasized throughout the body. 
For diagnoses and cancer treatment of most solid cancer types a staging system called TNM 
has been accomplished. T refers to the tumor and an added number to the size of the primary 
tumor and is graded from 1 to 4, whereas the size increases with the number. The parameter N 
should give an insight in the degree of spread to regional lymph nodes and M reflects the 
presence of metastases. By means of this assessment, a decision towards the best treatment of 
the malign neoplasm like surgery, radiation therapy or chemotherapy, is made.  
The risk of getting diagnosed with cancer rises rapidly after a certain age (Figure 3). 
Therefore the need for early and precise diagnoses of any kind of cancer is unquestioned. The 
data in Figure 3 refer to a survey of SEER the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results, where a hypothetical cohort of 10 million alive birth were 
analyzed using standard statistical methods. Most of the data were collected in 1987-88 from 
SEER. 
A male person at age of 60 has for example a chance of 6.42% to be diagnosed with prostate 
cancer till he is 70 years old, but there is a chance of 16% that prostate cancer is diagnosed till 
the end of his life (http://seer.cancer.gov/). Further there exists a likelihood of about 40% that 
one gets diagnosed with cancer in a lifetime and a likelihood of 20% that this patient dies of 
this disease. (http://seer.cancer.gov/) 
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Fig.3: Lifetime risk of being diagnosed with cancer. Data consider both sexes and all ethnicities. Incidence data 
are from the SEER 17 areas San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, 
Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding 
SF/SJM/LA, Kentucky, Louisiana and New Jersey. Source: National Cancer Institute 
(http://srab.cancer.gov/devcan/) 
 
 
1.2.2 Breast cancer 
 
Breast cancer is the most common type of cancer in female population. For women there is a 
likelihood of 12% to get diagnosed with breast cancer and a probability of 2. 8% to die from 
this illness in a lifetime (http://seer.cancer.gov/). A death rate of 2. 8% implies 411 000 death 
among female population worldwide per year (Parkin et al., 2005). 
Generally, a malign neoplasm in the area of the breast can emerge from milk ducts in 70 to 
80% of all cases or from the lobules of the breast in 10% of incidences. Other types like 
medullar, mucinous, mucoid or colloid breast cancers are rare, but treatment and diagnosis are 
similar to ductal and lobular breast cancer (Watson, 2001). 
If two or more persons in a family get diagnosed with breast cancer there may be a genetic 
predisposition for this illness in this family due to a germ line mutation in the breast cancer1 
(BRCA1) (17q21) or BRCA2 (13q12.3) gene. Current studies revealed that about 20% of all 
breast cancer incidences arise from a mutation of the BRCA1- or BRCA2-gene. (Risch et al., 
2006). 
These genes belong to the tumor suppressor genes, where a loss of function leads to a cancer 
predisposition. In this case, the DNA repair system is impaired, because the zinc finger 
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motive of the BRCA1 protein binds to branch DNA structures and prevents form diverse 
nuclease digestions. Further it promotes the DNA repair by NHEJ or HR (Chistiakov et al., 
2008). 
BRCA2 has a similar function as key protein in double strand break repair. Both proteins, the 
BRCA1 and BRCA2 gene product, interact with a large number of proteins, which are 
responsible for accurate DNA repair, and therefore a mutation of these two genes leads to an 
increased genomic instability (Durant and Nickoloff, 2005), which results in a probability of 
90% to develop breast cancer and 24% to develop ovarian cancer for BRCA1 mutation 
carriers (Risch et al., 2006). More than 1200 different mutations are known, which are 
distributed on all exons of the BRCA1 gene, showing almost all types of mutation, like single 
base exchange, insertion, deletion or inversion, leading to frame shift, miss-sense, nonsense 
and splice-site mutations. 
The prevalence of BRCA1 carriers in the overall population is estimated around 1%. 
Remarkably this value differs between ethnic groups, where Ashkenazi Jewish show a 
prevalence of 8%, whereas Asian American show a likelihood of 0,5% to carry a BRCA1 
mutation (John et al., 2007).  
The assessment of the hormone receptor status has developed to a key parameter molecular 
classification and is part of each tumor diagnoses process. Using immunohistochemistry of 
the tumor markers estrogenic-receptor (ER) for the steroid hormone “17 – estradiol” as well 
as Progesterone Receptor (PR) and Her2 are stained and analysed. The expression of the 
tumor-markers, ER and PR is linearly related to poor prognoses of breast cancer ((Sherman et 
al., 2007). In other words, the risk of a malign neoplasm increases with a positive hormone 
receptor status. 
An early diagnosis of cancer is essential, because early treatment improves survival. The 
death rate of the patient rises in the first five years after diagnoses to a value of 12%, after 
another five years to 20% (http://seer.cancer.gov/). A cheap and minimal invasive diagnostic 
test that could be accomplished by applying the results of diverse studies performed on blood 
sera of patients, may contribute to a simplification of the early recognition of cancer (Anker et 
al., 2003).  
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1.2.3 Tumor predisposition syndromes associated with breast cancer 
 
Cancer may have hereditary causes, but other effects are said to have a higher impact on the 
risk of developing a tumor. These carcinogens can be found in every area of life and the vast 
majority of all cancer incidences are said to be due to such agents. Further exposure to UV-
radiation and nuclear radiation as well as some retro viruses were brought in close connection 
to the arising of cancer (Juzeniene et al., 2009). 
One of the first approaches to understand the development of cancer is the two hit model of 
the group around Alfred G. Knudson. They produced the direct evidence that cancer can arise 
in a few steps as two via statistical analyses of hereditary and sporadic retinoblastoma in the 
1970ies (Knudson, Jr., 1971). Several other genetic changes can lead to a cancer 
predisposition, like a germ line mutation of the gene TP53, which is called Li-Fraumeni 
syndrome (LFS). This tumor suppressor gene is also known as P53, a DNA binding protein 
that induces cell cycle arrest, apoptosis and changes in metabolism. Also somatic mutations 
and aberrant methylation are observed at this locus (discussed in the next section). The 
proportion of cases in breast cancer is very low. Only about 1% of developed breast cancers 
bear such a P53 germ line mutation. A germ line mutation of this gene also leads to higher 
rates of brain cancer, childhood adenocortical carcinoma (ACC), gastric cancer and lung 
cancer (Hodgson et al., 1995). 
Sporadic cancers are caused by somatic mutations, aberrant methylation and various other 
causes, which were partially mentioned above. 
Although, the larger fraction of breast cancer cases can be rated as sporadic cancer, a twin 
study performed by Lichtenstein P. (Lichtenstein et al., 2000) pointed out that 27% of tested 
cases were due to a heritable factor. The difficult search for an origin of sporadic cancers 
produced the cancer stem cell hypothesis (CSC), which describes an alternative scheme to the 
“stochastic model” of carcinogenesis. This model (CSC) proposes that multiple mutations or 
other events, like aberrant methylation of a random single cell occurs and is followed by a 
clonal selection of the fittest cancer cell. Recently a model was proposed (Figure 4) that is 
based on the observation of the different cancer phenotypes and it combines both approaches 
in one integrative hypothesis (Melchor and Benitez, 2008). This hypothesis about the origin 
and the development of breast cancer was created upon the detailed analyses of common 
cancer phenotypes like the ERBB2 cancer cell line, which over-expresses the ERBB2 locus 
and the genes located in 17q11. Another appearance of breast cancer cells is the luminal B 
phenotype. In this case, the cells exhibit many cell surface proteins comparable to basal-like 
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cancer cells, but the cells are estrogen receptor positive. In the course of this analyses of the 
certain cancer phenotypes Melchor M. and co-workers (Melchor and Benitez, 2008) found 
many similarities between the different pathways concerning the arising of cancer, and many 
different pathways that may result in the same cancer phenotype. These findings finally lead 
to this model (Figure 4). 
This hypothesis may actually be applicable to the development of cancer for the majority of 
breast cancer and it provides a good insight of the genetic events that lead to cancer and 
highlights coherences that may facilitate the analyses of breast cancer data. Further, this 
already simplified illustration (Figure 4) emphasizes the complexity of the illness, which we 
and many other researchers try to understand. 
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Fig.4: Integrative approach of the CSC hypothesis and the stochastic model. The picture starts with the 
development of a normal breast cancer cell including their cytokeratin status. Red-labelled boxes represent the 
basal like cancer cell phenotype including their carcinogenesis (section A). Blue-labelled boxes show ERBB2 
phenotype, and so on. Yellow boxes in section A indicate the most frequent pathway of the breast cancer class. 
Crossed out boxes represent the inability of cells exhibiting a BRCA1/2 mutation to undergo this pathway 
(ERBB2). The thicknesses of the arrows at the bottom indicate the genomic instability observed in the certain 
cancer phenotypes. Adopted from (Melchor and Benitez, 2008) 
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1.2.4 Tumor-suppressor-genes and Oncogenes  
 
The typical tumor-suppressor gene is expressed in normal tissue cells and its inactivation in 
cancer cells leads to growth advantages of these tumor cells. Frequently this occurs upon 
methylation of the promoter region of this certain genes, which are the main targets of our 
research. 
One example for such a gene, which is also found methylated in human blood serum of breast 
cancer patients, is RASSF1a. The promoter hypermethylation of this gene is virtually found in 
every type of invasive cancers and the silencing goes along with expression-changes from 
hundreds of genes(Kioulafa et al., 2009). Amongst others the gene product of RASSF1a 
interacts with XPA, a DNA repair protein, and impair cyclin D1, which induces cell cycle 
arrest. 
Oncogenes have the antithetic effect. They are silenced in normal tissue, and their expression 
facilitates tumor progression. Prominent examples are genes of the Src family (v-src sarcoma; 
Schmidt-Ruppin A-2), which are believed to play a critical role in cancer development. The 
gene products of this family are kinases, which are involved in diverse pathways that enable 
the rapid growth of cancer cells. Recent reports show that an inhibition of these gene products 
can slow down tumor cell proliferation significantly (Laird et al., 2003). 
 
 
1.2.5 Epigenetic events in cancer development 
 
Hereditary cancer can also be due to aberrant methylation of certain genes. In this case a 
disruption of the imprinting mechanism leads to a cancer predisposition. Insulin-like growth 
factor 2 (IGF2) is expressed differently in healthy individuals depending whether the mother 
or the father inherits the allele. An aberration of the methylation pattern in this genomic 
region (11q15) leads to a cancer predisposition, which is called Beckwith-Wiedemann 
syndrome that is associated with embryonic tumors like Wilms´tumor or rhabdomyosarcoma. 
In this case the imprinted cluster of at least 12 genes including IGF2 and H19 is methylated 
incorrect in early development, which leads to this predisposition (Weksberg et al., 2003). 
A loss of this coordinated regulation was recently also observed in a certain fraction of 
sporadic gastric cancer patients. In this case, the IGF2, an early mitogenic factor and cell 
proliferation-enhancing factor in healthy individuals, is hypo-methylated in one allele in 
cancer cells, which leads to biallelic expression of IGF2. Recent studies show that this 
hypomethylation is not due to environmental influences, but were found in normal tissue and 
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in malign neoplasm of patients too, which indicates that the methylation status of IGF2 in 
gastric cancer may be an inherited factor (Lu et al., 2009). 
Another current hypothesis proposes the involvement of the polycomb-regulated genes in the 
development of cancer predisposition due to methylation events. These polycomb group 
proteins, mainly transcription factors, are essential for human development. The regulation of 
these genes occurs via the polycomb repressive complex 2 (PRC 2), which silences genes 
upon histone trimethylation and targets over 1800 genes (Lee et al., 2006). Researchers, 
investigating the epigenetic changes in cancer progression, observed an enrichment of PRC 2 
target genes in several methylation screenings and postulated therefore a model for aberrant 
promoter hypermethylation in several cancers including breast cancer (Figure 5) 
(Widschwendter et al., 2007). 
The mechanisms of PRC-DNMT cross talk is till today not fully understood, but methylation 
data for PRC2 targets, which are methylated at a higher frequency at certain phenotypes, 
suggest a model like figure 5. This theory suggests that the PRC-DNMT crosstalk occurs at 
low frequency in an early stage of development and does not influence normal differentiation, 
further this results in a cell with a predisposition for cancer development. A further indication 
for the accuracy of this model is tumor specific promoter methylation of genes (e.g. 
NEUROD1), which are not expressed in normal tissue but serve as methylation markers in 
cancer development without any known function in tumor progression of breast cancer or B-
cell lymphoma (Pike et al., 2008). 
The most conclusive evidence for this model is a 12-fold more likely cancer specific 
methylation of PRC2 targets observed by Widschwendter (Widschwendter et al., 2007). 
Further, McCabe and co workers investigated CpG islands, which are targets of DNMT and 
showed an aberrant methylation in cancer cell lines in diverse “knock-down” experiments 
(McCabe et al., 2009). These researchers figured out that about 50% of this so-called 
methylation–prone CpG islands were targets of the SUZ12, the binding domain of PRC2. This 
finding also strongly suggests a DNMT-PRC 2 crosstalk. 
Applying the stochastic model of cancer development, many researchers screen for 
methylation events in cancer progression that lead to a growth advantage of the cancer cell, 
facilitates invasive growth, prevents the cell from apoptosis or accelerates metabolism and so 
on. This approach is mainly performed upon broad screening methods of cancer samples of 
multiple cancer types and has lead to the discovery of large cohort of tumor suppressor genes 
and oncogenes aberrantly expressed upon methylation. Due to the very heterogeneous cancer 
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subclasses in every cancer type, a clear determination of markers with prognostic significance 
or fitting as drug target is very rare. 
Therefore researchers recently search for methylation signatures. In the field of breast cancer 
Roll et al. tried to find different methylation signatures in various breast cancer cell lines by 
over-expression of DNMT 1, 3a, 3b, which is thought to be an early event in carcinogenesis 
(Roll et al., 2008). Within their 12 tested breast cancer cell lines they could determine two 
phenotypes: hypermethylator cell lines, where the over-expression of all DNMT gene-
products resulted in a significant increase of methylated CpG island and low-frequency 
methylator cell lines. These two phenotypes base on the methylation and expression of six 
cancers specific methylated genes and further provided the finding that this phenotype can be 
associated with primary basal-like breast cancers. 
Hence the conclusion can be made that CIMP (CpG island methylator phenotypes), which 
were initially found exclusively in colon cancers (Dahlin et al., 2010), also can be determined 
in breast cancer (Paluszczak et al., 2010). This approach provides the possibility of more 
detailed investigation of cancer progression on the basis of methylation analyses and may 
enhance the broad search for new methylation markers. 
 
 
 
Fig.5: In normal tissue the regulation of polycomb group genes occurs upon binding of PRC2 and PRC1. The 
hypotheses about creation of cancer precursor cells bases upon the recruitment of DNMT, a de novo 
methlytransferase that methylates the DNA in early precursor cells. The procedure results in an alternative 
silenced gene, at which a re-induction of expression is facilitated in cancer cells. Adopted from (Widschwendter 
et al., 2007) 
 
 
1.2.6 Methylation screening 
 
In principle DNA methylation analysis may be divided into three approaches, which are 
enzyme digestion, affinity enrichment and sodium bisulphite conversion of the DNA. They 
can be found in figure 6 and are discussed in brief below. Further one may distinguish 
between genome scale approaches and loci specific methods, where only a few promoters 
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were characterized by single base pair resolution. Genome wide approaches like DMH 
(differential methylation hybridization), RLGS (restriction landmark genome scanning) or 
MIRA (methylated CpG island recovery assay) have the disadvantage not to reach a single 
base pair resolution and a creation of a precise epigram of a gene locus was not possible 
(Laird, 2010). Next generation sequencing combines these two approaches: a genome wide 
analysis of a methylome and a resolution of a single base pair. Therefore it has been already 
combined with each of the thee principle approaches (figure 6) to determine the methylation 
status of DNA (Laird, 2010). 
MSP, methylation specific PCR, is till today the most prominent method to assign the 
methylation status of certain genomic loci. By this method the DNA is treated with sodium 
bisulfite, which converts all unmethylated cytosines bases to uracil bases. Subsequently 
primers, specific for methylated or unmethylated targets, are applied to perform an 
amplification that allows the detection of the differentially methylated targets. 
Another option elucidating DNA methylation is using MSRE´s, methyl sensitive restriction 
enzyme digestion, which are blocked by methylated CpG or digest exclusively methylated 
CpGs. Upon MSRE-digestion all unmethylated/methylated targets are digested and the 
un/methylated DNA, which is not affected by the digestion, can be amplified and detected. 
Dependant on which set of enzymes are used, McrBC for digestion of methylated DNA or 
HpaII, Hin61 etc. for digestion of unmethylated DNA, the respectively other fraction (i.e. 
methylated or unmethylated) can be analysed. 
MeDIP is a rather new approach to identify differentially methylated DNA sequences. Here 
the DNA gets sonicated and denatured, then antibodies specific for 5-methylcytosines are 
used to precipitate the methylated DNA, which subsequently get labelled and hybridized on a 
micro array or sequenced by new high throughput methods (Mohn et al., 2009). Another 
possibility to perform an affinity enrichment on methylated DNA (not shown in figure 6) is 
provided by the utilization of methyl binding proteins for loci specific analyses or at more 
recent approaches in combination with next generation sequencing (NGS) (Li et al., 2010). 
The Next Generation Sequencing approach (developed by 454) to determine methylated DNA 
regions is a special application of pyrosequencing. The procedure of pyrosequencing is based 
on “Sequencing by Synthesis” measuring the release of pyrophosphate. 
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If the template DNA for this reaction has underwent a sodium bisulfite conversion a precise 
epigram of each template DNA strand can be created. 
 
 
 
Fig.6: Overview of principles of DNA methylation analysis. AIMS (amplification of inter-methylated sites), 
BC–seq (bisulphite conversion followed by capture and sequencing); BiMP (bisulphitemethylation profiling), 
BS (bisulphite sequencing), BSPP (bisulphite padlock probes), CHARM (comprehensive high-throughput arrays 
For relative methylation), COBRA (combined bisulphite restriction analysis), DMH (differential methylation 
hybridization), HELP (HpaII tiny fragment enrichment by ligation-mediated PCR; MCA, methylated CpG island 
amplification), MCAM (MCA with micro array hybridization); MeDIP, mDIP and mCIP (methylated DNA 
immunoprecipitation), MIRA (methylated CpG island recovery assay), MMASS (based-based methylation 
assessment of single samples), MS-AP-PCR (methylation-sensitive arbitrarily primed PCR), MSCC 
(methylation-sensitive cut counting), MSP (methylation-specific PCR), MS-SnuPE (methylation-sensitive single 
nucleotide primer extension), NGS (next-generation sequencing), RLGS (restriction landmark genome 
scanning), RRBS (reduced representation bisulphite sequencing; –seq, followed by sequencing), WGSBS 
(whole-genome shotgun bisulphite sequencing); Adopted from (Laird, 2010) 
 
 
1.2.7 “Methylation” drugs 
 
One of the prime reasons, why the understanding of methylation events in cancer is that 
important and therefore is addressed by many researchers, is that methylation is a reversible 
process. This implies that methylation is a preferable drug target for therapy of cancer 
patients. 
Recently some demethylating agents like 5-azacytidine (Vidaza) and 5-aza-2'-deoxycytidine 
(Decitabine) have been tested on cancer cell lines and researcher suggest these agents as an 
alternative cancer treatment (Datta et al., 2009). These agents degrade DNMT1 upon a 
proteasomal pathway, which leads to the reactivation of tumor suppressor genes like P16, 
MLH and TIMP3 by de-methylation and re-expression and does not show significant toxity to 
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the used cancer cell lines. The FDA (U.S. Food and Drug Administration) approved these 
drugs already for the treatment of Myelodysplastic syndrome (MDS) (Szyf, 2009). 
A quite different approach to influence methylation in cancer progression is the recruitment of 
MBD-2, a methyl-binding domain protein. In vitro translation of a recombinant form of 
MBD-2 induced re-expression of silenced genes in cancer. On the other hand “knock-down” 
experiments in vitro and in vivo triggered an inhibition of tumor growth, invasiveness and 
metastases, which let speculation about antisense oligonucleotides, siRNA inhibitors, and 
MBD2 antagonists as promising cancer drugs. (Szyf, 2009). 
 
 
1.2.8 DNA in serum  
 
The prognostic potential of cell free nucleic acids in plasma and serum caused a great deal of 
attention in current efforts to improve diagnoses of diverse malignant cancerous diseases (Lo 
and Chiu, 2009). Various approaches in this field like the determination of genetic 
aberrations, the methylation status of the DNA (Fleischhacker and Schmidt, 2007) and the 
DNA level (Anker et al., 1999) have been reported to have diagnostic potential. 
In the sector of breast cancer diagnoses the prevailing situation is the same, although the 
current diagnostic techniques as physical examinations or diverse imaging methods are 
convincing the need for a simple blood test would be high. Many methylation markers for 
breast cancer determination of tissue biopsies are already well established, but the search for 
aberrant methylated DNA in serum has till now not reached this advance. Although the 
screening for such markers is a consistent proceeding process and recent reports 
demonstrated, for example, aberrant methylated promoter region of RASSF1a even at about 
20% of tested patients before they got diagnosed with breast cancer, the panel of evaluated 
breast cancer markers in blood serum is low (Yazici et al., 2009) (Van, I et al., 2009) (Jing et 
al., 2008) (Shukla et al., 2006) 
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2. Aim of the thesis 
 
 
In this work we optimized and evaluated different serum DNA isolation strategies and further 
assume the DNA binding characteristics of the MBD protein, which was one of our DNA 
isolation approaches under test. 
Moreover we tested several genome wide amplification methods for the enrichment of the 
methylated DNA in our experimental setup through a comparison of three different 
approaches. 
Finally we aimed at the discovery of methylation markers for clinical diagnoses in serum of 
breast cancer patients by performing a screening for methylation markers using a panel of 360 
genes for multiplexed amplification of the genome wide amplified DNA followed by 
hybridization. 
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3. Material and Methods 
 
3.1 Patients and Serum sample preparation 
 
Blood was taken from 12 healthy adults, age and sex matched, for methods setup. After 
incubation in Vacuette 9ml Z Serum Clot Activator (Greiner Bio One) for 30 minutes the 
samples were centrifuged at 1,800-x g for 10 minutes at room temperature. Aliquots of 2ml 
were stored at -80°C.  
Serum samples (n=82) obtained form the AKH Wien (General Hospital Vienna) were taken 
between July 2002 and November 2006, centrifuged at 1000 x g for 15 minutes and stored in 
200µl aliquots at -80°C until usage. For this study serum specimen of 40 patients with a 
malign neoplasm, sera of 12 patients with a benign tumor, 6 patients with a carcinoma in situ 
and 24 normal controls were processed (table 4). 
 
 
3.2 DNA isolation from serum 
 
3.2.1 Roche High pure template preparation kit 
 
DNA isolation from serum using common silica membrane based isolation strategy was 
performed applying the Roche High pure template preparation kit (Roche Applied Science). 
The protocol was adapted according to Müller H. M. (Muller et al., 2003). Isolation was 
performed according to manufacturer’s instruction except the following protocol steps: the 
800µl of serum samples were split into 2 aliquots of each 400µl and each mixed with 400µl of 
Roche Binding Buffer and 80µl ProteinaseK (Fermentas, 20mg/µl). After 15 minutes of 
incubation at 55°C, 200µl isopropanol was added to each aliquot. This aliquot was mixed and 
twice a volume of 1080µl (i.e. two aliquots) was loaded to the column subsequently followed 
by a centrifugation step of 1 minute at 8000-x g. The flow through after each centrifugation 
was transferred back onto the same column and centrifuged again. Inhibitor-removal and 
washing steps were performed according to manufacturers´ protocol, but the DNA was eluted 
in 55µl of elution buffer. 
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3.2.2 Qiagen Blood midi kit 
 
Alternatively DNA from 1ml serum was extracted with Quiagen DNA Blood Midi kit for 
large-scale genomic and viral DNA purification form whole blood, plasma, serum and body 
fluids (Quiagen, Hilden, Germany) according to the manufactures instructions. Except the 
elution volume was lowered form recommended 200µl to 100µl. 
 
3.2.3 ZR Serum DNA kit 
 
The ZR Serum DNA kit (Zymo Research, U.S.A.) was applied, as recommended in 
manufacturers instructions, to isolate DNA form 800µl serum in a silica bead based manner. 
 
3.2.4 MBD based Isolation 
 
 3.2.4.a Bead assembly 
 
The Escherichia coli strain BL21, containing the pET6HMBD plasmid, kindly provided by 
Sally H Cross, was grown in Luria-Bertani medium with 30µg/ml chloramphenicol and 
50µg/ml ampicillin. Recombinant protein expression was induced by adding IPTG to an end 
concentration of 0,4mM, at a measured optical density (600) of 0,6. E.coli cells were broken 
up by repeated sonication in Lysis Matrix A tubes (MP Biomedicals). The bacterial extract 
was then centrifuged at 13,000rpm for 10 minutes and supernatant was transferred to a new 
vial. Centrifugation step was repeated until all cell debris was removed. The pellet was 
resuspended in buffer A in ratio of 1g pellet plus 2ml buffer A and stored at –20°C until 
usage.  
200 µl of a 50% suspension of Ni-Sepharose beads  (Adar Biotech, Rehovot, Israel) were 
equilibrated through resuspension in 500µl water, followed by centrifugation 1min 1000 x g 
and removal of the supernatant from the beads. The beads were then equilibrated by adding 
500µl buffer A (20mM HEPES, 100mM NaCl, 10% glycerol, 20mM beta-Mercaptoethanol 
(added daily fresh), 0,5mM PMSF, 0,1mM TritonX, pH=8) and centrifuged at 1000g for 
1min. This procedure was repeated twice. Finally the beads were resuspended in 100µl buffer 
A. His-tagged HMBD-protein was bound to the equilibrated beads by addition of 800µl 
bacterial extract (derived from approximately 300mg E.coli wet cell weight) and 800µl 2x 
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buffer A and incubation for two hours on ice at which the beads were held in suspension upon 
repeated mixing. 
Bead-HMBD protein-complexes were washed twice by adding 500µl wash buffer (buffer A, 
plus 10mM Imidazol) followed by centrifugation at 1000-x g for 1min. The proteins were 
either eluted from beads with buffer A plus 500mM Imidazol to perform a SDS page gel or 
residual E.coli DNA was removed with buffer B (1,5M NaCl, 20mM HEPES, 20mM -
Mercaptoethanol, 0,5mM PMSF, 0,1mM TritonX, pH=8 buffer). To apply this fraction for 
DNA isolation procedure, the beads were resuspended in 100µl Buffer A. Protein 
concentrations were measured with a BioRad Dc-Protein assay (Biorad, Hercules, California). 
Protein purification was visualized on a SDS page gel (NuPage Novex Bis-Tris Gel) by 
applying aliquots of each purification step onto the gel. Proteins were denatured via 10 
minutes at 70°C, mixed with loading dye (Biorad, Hercules, California), and loaded onto the 
gel, where 200V were applied for 35 minutes. 
 
 3.2.4.b DNA extraction 
 
For DNA extraction using the MBD immobilized Ni-beads 1 ml of serum was incubated with 
1 ml of 2x buffer A and 60µl of prepared 50% bead/Protein-complex suspension in buffer A 
for 2h on a thermo mixer (Eppendorf) at 450 rpm at room temperature. After centrifugation 
1000 x g for 1 min. the reaction was separated into a bead fraction, which was used for further 
DNA isolation protocol, and a serum fraction, which was tested for protein integrity by a 
protein micro array, suitable to detect auto-antibody profiles. The DNA-MBD complex was 
washed twice with buffer C (20mM Hepes, 100mM NaCl, 10% glycerol, pH 8) and 
resuspended in 145 µl Tris-Cl buffer, pH=8. To elute the DNA from the MBD/bead-complex, 
a ProteinaseK-digestion was performed in a volume of 150µl by adding 5µl ProteinaseK 
(Fermentas, 20mg/ml) to the resuspended beads. The reaction was incubated at 55°C for 20 
min followed by heat inactivation of the ProteinaseK. DNA was then isolated from the 
ProteinaseK supernatant using Quiagen MinElute columns. Purification was performed 
according to manufacturers` instruction with an elution volume of 17µl. 
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3.3 DNA concentration measurement 
 
DNA concentration was measured with “Quant it” Pico Green (Invitrogen) according to the 
manufacturers protocol with a reduced reaction volume of 100µl. Samples and standards were 
excited at 480nm and emission was read at 520nm using a BioRad IQ5 Real time PCR 
detection system. A five-point lambda DNA standard curve ranged from 15pg/µl to 250pg/µl 
in a measuring volume of 100µl. Per serum isolate a volume of 5µl was applied to the “Quant 
it” Pico Green assay. 
DNA concentrations within a range of 15ng/µl to 1000ng/µl were measured on a Nanodrop 
Photometer, measuring the absorption of the DNA samples at 260nm. 
 
3.4 Enrichment of methylated DNA 
 
As illustrated in figure 11 in the section “Serum processing workflow” on page 37, our 
methylation screening approach is suitable for a genome wide CpG island methylation screen. 
To meet the requirements for such an approach two restriction enzyme digestions and a 
ligation is necessary. The first restriction digestion with FspBI fragments the genomic DNA 
and creates amplify-able DNA fragments sizes as well as a TA-overhang, which is necessary 
for the subsequent ligation. The second restriction digestion (i.e. after the ligation) cuts all 
unmethylated fragments that bear a recognition site for the methyl sensitive restriction 
enzymes. In this way only successful ligated methylated DNA fragments are targets for the 
genome wide amplification, to enrich the methylated fraction of the genomic DNA. 
 
3.4.1 Creation of sticky ends for ligation dependant WGA 
 
Serum DNA (acc. 3.2.1; conc.: 10-20ng) extracted by Roche High pure template preparation 
kit was used for restriction digestion with FspBI (10 u/µl, Fermentas). In a total volume of 
56,6µl we reached a 1x concentration of 10 x buffer Tango containing BSA (Fermentas) by 
adding 5,6µl. The creation of TA-overhangs was assured by adding 1µl FspBI (10 u/µl, 
Fermentas). The reaction was incubated over night at 37°C and heat inactivated by heating the 
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samples to 65°C for 15 minutes. We assembled a mix including all components (i.e. reaction 
buffer and enzyme) except the sample at first, and then the combined reagents were aliquoted 
in this case 6,6µl per vial. Finally the sample (50 µl) and controls were added to the vials to 
start the reaction. This procedure was performed at all following DNA manipulation and 
amplification reactions.  
 
3.4.2 Circularization of DNA samples for rolling circle amplification 
 
To create DNA circles upon self-ligation of DNA fragments with TA overhangs the samples 
were diluted to a concentration smaller than 1 ng/µl. Therefore we used the whole reaction 
volume of the previous restriction (acc. 3.4.1) digestion of 56,6µl and added 0,283µl of ATP 
(100mM, Fermentas) to reach the recommended ATP concentration of 0,5mM in the sample 
volume. Then 24,3µl T4 Ligase buffer (10x Fermentas) was added as well as 215,8µl water 
(Mayrhofer Phamazeutika, Aqua Bidestillata), to obtain a reaction volume of 300µl, which 
was necessary to guarantee an appropriate dilution of the DNA. This mix was incubated for 5 
minutes at 42°C to dissolve any DNA-concatemers. After the samples were cooled on ice, 3µl 
of T4 Ligase (5u/µl, Fermentas) were added to every sample. So a reaction end volume of 
300µl per sample was maintained. The ligation was performed at 22°C for 8 hours followed 
by heat inactivation at 75°C for 15 minutes.  
 
 
3.4.3 Adaptor Ligation 
 
For adaptor ligation mediated amplification an in house developed protocol was applied, 
where first two complementary ssDNA oligos were mixed to create the ds.adaptor for 
ligation. Therefore we used oligo A with the sequence: 5´ - TATGAGACTGACTACCAGAT – 3´ 
and oligo B with the sequence: 5´ - AGTTACATCTGGTAGTCAGTCTCA – 3´. dsDNA were 
created by mixing two equal volumes (i.e. 10µl) of the two oligos (100µM, Microsynth) 
followed by heating them to 95°C and a stepwise cooling of the reaction. Thus assembled 
adaptors were used in the ligation reaction, that consisted of 3,9µl FspBI digested genomic 
DNA sample (MCF7 cell line DNA), 2µl adaptors, 2µl T4 Ligase buffer (Fermentas), 10,1µl 
water and 2µl T4 Ligase (5u/µl, Fermentas). 
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3.4.4 Purification of ligation reaction 
 
Each ligation reaction (acc. 3.4.2) was divided into 3 aliquots á 100µl, which were combined 
with 300 µl binding buffer of the MinElute reaction clean up kit (Quiagen, Hilden, Germany). 
The three aliquots per reaction were applied successively to one column. The purification 
protocol was performed according to the manufacturer’s instructions and the DNA was eluted 
in 10µl of elution buffer. 
 
 
3.4.5 Methyl sensitive restriction digestion 
 
The entire eluate of the purified ligation reaction (acc. 3.4.4) was included into a methylation 
sensitive restriction digestion. We combined 10µl DNA sample (acc. 3.4.4) plus 1,5µl buffer 
tango (10x with BSA, Fermentas), plus 1.6µl of restriction enzyme mix and 1,9µl water to 
obtain a final volume of 15µl. The enzyme mix consisted of 0.4µl of each of the four 
methylsensitve restriction enzymes (table 1) namely HpaII (10u/µl, Fermentas); Hin6I 
(10u/µl, Fermentas); AciI (10u/µl, New England Biolabs) and HpyCH4IV (10u/µl, New 
England Biolabs). The reactions were incubated at 37°C over night and heat inactivated at 
70°C for 20 minutes. 
 
 
 
Table 1. Restriction enzymes for methyl sensitive digestion 
 
Name Recognition Site blocked by mCpG 
 
HpaII 5´-C^C G G-3´ yes 
 3´-G G C^C-5´ 
 
Hin6I 5´-G^C G C-3´ yes 
 3´-C G C^G-5´ 
 
AciI 5´-C^C G C-3´ yes 
 3´-G G C^G-5´ 
 
HpyCH4IV 5´-A^C G T-3´ yes 
 3´-T G C^A-5´ 
 
 33
 
3.5 Genome wide amplification 
 
3.5.1 Rolling circle amplification 
 
The rolling circle amplification reaction consisted of 13,48µl water; 3µl RepliPHI reaction 
buffer (10x, RepliPHI phi29 polymerase set, Biozym); 2,7 µl N10 Primer (OD = 125, 
Microsynth); 2,82µl dNTP (25mM, RepliPHI phi29 polymerase set); 1µl phi29 polymerase 
(100 u/µl, RepliPHI phi29 polymerase set) and 7µl sample (i.e. restriction reaction), to obtain 
an end volume of 30µl. Templates in the reaction mix were denatured prior to the 
amplification by heating the reaction mix at 95°C for 5 minutes followed by cooling on ice 
water for another 5 minutes. Then 1µl of the phi29 polymerase was added and the reaction 
was incubated at 30°C overnight. The reaction was stopped by incubation at 65°C for 10 
minutes. 
 
3.5.2 APA-PCR 
 
Adapter mediated genome wide amplification was performed with 20µl purified restriction 
digestion (see section Adaptor Ligation), 10µl dNTP (2mM, Finnzymes), 5µl primer (oligoA, 
100pm), 49, 6µl water and 0,625µl Phusion polymerase (Finnzymes). The PCR was 1 min at 
98°C followed by 30 cycles of denaturation at 98°C for 20 sec, annealing and extension at 
68°C for 1 min, 40 sec and final extension of 5 min at 72°C. 
 
 
3.5.3 Whole Genome Amplification kit from Sigma-Aldrich 
 
The genome wide amplification using Genome Plex WGA1 kit (Sigma-Aldrich) was 
performed according to manufactures instruction. 10ng of genomic MCF7 DNA, without 
previous treatment, served as template for these reactions. 
 
3.6 Control PCR 
 
To ascertain a complete methylation-sensitive restriction digestion we performed a PCR in a 
multiplex manner, where differentially methylated DNA fragments of the digested DNA 
samples served as template for PCR amplification (Weinhaeusel et al., 2008). In a total 
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volume of 20µl a fraction of 13,6µl water plus 1,66µl 2mM dNTPs (Fermentas), plus 1,04µl 
DMSO (Sigma-Aldrich), 0,5µl Primermix (table2), 2µl 10x Hotstart-Taq-PCR buffer 
(Quiagen, Hilden, Germany), 0,125µl Hot star Taq (5u/µl, Quiagen, Hilden, Germany) and 
1µl sample were mixed and used for amplification. The PCR was 15 min at 95°C followed by 
40 cycles of denaturation at 95°C for 30 sec, annealing and extension at 68°C for 1 min, 20 
sec and a final extension of 7 min at 72°C. The 2mM dNTP solutions were obtained by 
mixing using 20µl of each dNTP (dATP, dCTP, dGTP, dTTP 100mM, Fermentas) combined 
with 920µl of water. 
 
 
 
Table 2. Primer list multiplex control PCR 
 
Name  sequences prod. Length cut sites 
 
PitXa fw 5´ - TCCCCGCTGCCCTGGCGCTC - 3´ 315bp 
 rev 5´ - GCTGCGCGGCTGGCGATCCA – 3´  14 
 
contrA fw 5’ – TGGGCAGGGGAGGGGAGTGCTTGA –3’ 240bp 
 rev 5’ – TGACCCCTGGCACATCAGGAAAGGGC –3’  0 
 
XIST fw 5´-TGCGGCAAGCCCGCCATGATG - 3´ 200bp 
 rev 5´- GCATGGTGGTGGACATGTGCGGTC – 3´  4 
 
contrB fw 5’ – TCACAGAGCCAGGCAAGCATGGGTGA –3’ 175bp 
 rev 5´– GCGAGCCTGCTGCTCCTCTGGCACC – 3’  0 
 
RB1 fw 5’ – AGCGTCCCAGCCCGCGCACC –3’ 138bp 
 rev 5’ – CCCCGCCCGGCAACTGAGCG – 3’  9 
 
SNRP fw 5’ - CGCTCGCATTGGGGCGCGTC - 3’ 124bp 
 rev 5’ – TGCCCACTGCGGTTACCCCGCAT –3’  3 
 
All primer pairs were used in one reaction, where we applied appropriate amounts of a 100µM primer stock 
solution to reach a concentration of 0, 3µM per primer pair.  
“Cutsites” refers to the number of recognition sites per fragment including all four methylsensitve restricion 
enzymes (table 1) used in our experimental setup. 
 
 
3.7 qPCR tests 
 
All qPCR reactions were performed in 384 well format on a Roche Light Cycler 480. A 
reaction volume of 10µl contained 0,125µM of each Primer, 0,3U of Hotstart Taq (Qiagen), 
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5% of DMSO containing Sybr green to reach a dilution of 0,5x in the reaction and 166µM 
dNTP-mix. 2µl of silica membrane based serum-DNA isolates served as template per qPCR 
reaction, whereas the qPCR reaction of serum or plasma isolates processed with MBD was 
performed with 1µl. In both cases about a 0,5ng to 1ng was used per reaction. Ct calls and 
melt curves were analysed using the Roche Light cycler 480 software, to guarantee that only 
Ct-calls of PCR product with an appropriate melt curve were used for the comparison of the 
Ct-calls (section: Results; MBD based isolation; figure 8).  
The PCR program was identical to the multiplex PCR program with the exception that for 
qPCR analyses 50 cycles were performed. Table 3. Primer list Enrichment of methylated 
DNA fragments 
 
 
 
Gene-Symbol  sequence prod. length methylated 
 
SALL3 fw 5’ – GGCGGGGAAGGCGACCGCAG –3’ 
 rev 5’ – TCCCCGGGCGGCCATTAGGCA – 3’ 212bp no 
 
ESR1 fw 5’ – CCGCCGCCAACGCGCAGGTC – 3’ 
 rev 5’ – GCCGGCCTCGCGCACCGTGT – 3’ 239bp no 
 
CHFR fw 5’ – GCGGTCCGCGAGTGGGAGCG –3’ 
 rev 5’ – TGCAGACATTGGCGCGTTCCTCCA – 3’ 276bp no 
 
ZNF502 fw 5’- GGCCCCAGTCCACCTCTGGGAGCG –3’ 
 rev 5’ – GCCCTACGTCCGGGCAGCACGC – 3’ 207bp yes 
 
Primer sequences used in qPCR with MBD and silica membrane based serum DNA isolates for evaluation of 
MBD based DNA extraction approach (figure 8). The methylation status of the DNA fragments was ascertained 
on UCSC genome browser (http://genome.ucsc.edu/) applying the feature „HAIB Methyl-seq“ and „HAIB 
Methyl27“ to display the methylation status of diverse human cell lines. 
 
 
3.8 Agarose gels 
 
DNA electrophoreses was done using a 2% agarose gel (Sigma-Aldrich) in 1 x TBE 
containing 0,5 µg/ml ethidiumbromide (Merk). We used 6 x DNA loading dye (Fermentas) 
and Gene Ruler 100bp DNA Ladder Plus. (Fermentas) To achieve a separation of the PCR-
product bands and DNA fragments, gels were run at 155 V/ ~20cm was applied for 75 
minutes. 
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3.9 Multiplex PCR of 360 target DNA fragments 
 
Dr. Andreas Weinhäusel at the Austrian Institute of Technology developed the multiplex PCR 
and the following detection on a target specific micro array. The marker selections based on 
published work of (Widschwendter et al., 2007), (Shames et al., 2006). A collectivity of 360 
target PCR amplifications was divided into 16 reactions for 20-24 amplification products 
each. Thus each DNA sample was divided into 16 equal aliquots with 25ng input DNA per  
distinct multiplex PCR reaction, which enabled us to screen 360 target regions for elucidating 
DNA methylation markers. By the use of biotinylated reverse primers (100µM, Microsynth) 
the detection with streptavidin cy3 conjugates (Caltag Laboratories) on the target specific 
micro array was enabled.  
One reaction with 16-24 primer pairs, which had a concentration of 0,25µM per primer in a 
reaction volume of 11,5µl, consisted of 6,29µl water, 1,15µl reaction buffer (10x, PCR buffer, 
Quiagen), 0,92µl 2mM dNTP (100mM, Fermentas), 0,58µl DMSO (Sigma-Aldrich), 2,5µl 
primermix, 0,07µl Hot FirePol (Solis Biodyne) and 0,812µl sample. The complexity of this 
procedure made it necessary to create a mastermix of these reagents without sample and 
primers. Hence a volume of 167µl mastermix (i.e. 20 times one reaction) was combined with 
13µl sample (i.e. 400ng), for which one mastermix was created for all samples and controls 
and then divided into 167µl aliquots. This mixture of PCR reagents and DNA sample then 
was aliquoted into 16 vials with 9µl each, followed by addition of 2,5µl primermix 
(consisting of 16-24 primer pairs), using an eppendorf epMotion 5075-pipette roboter. The 
PCRs of 24 samples were carried out in 384 well plates. The PCR was 15 min at 95°C 
followed by 40 cycles of denaturation at 95°C for 40 sec, annealing 40 sec at 65°C, extension 
at 72°C for 80 sec and final extension of 7 min at 72°C. After amplification all 16 multiplex 
PCR reactions per sample were pooled. 
 
 
3.10 Hybridization and Detection of multiplex PCR products 
 
For the detection of the possible 360 PCR products we used a micro array, which was spotted 
at the AIT with an omnigrid machine (a1 Biotech) At this procedure 0,6nl of about 60nt long 
oligos with a concentration of 10µM, where each DNA oligo was complementary to one PCR 
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product, was spotted in triplicates on aldehyde coated glass slides (CEL Associates, VSS 25 
Silycated Slides Aldehyde). Each spot had a diameter of 100µm. One micro array consisted of 
360 different PCR product specific probes and several controls in triplicates. Three micro 
arrays were placed on one glass slide.  
 
3.10.1 Sample preparation 
 
The pooled PCR products (approximately 600ng DNA) were combined with hybridization 
buffer in a ratio of 1:1 to an end volume of 110µl. The hybridisation buffer was pre-warmed 
to assure a complete dissolving of all components. The hybridization buffer consisted of 7x 
SSC (20x, Invitrogen), 0,6% SDS (20%, Sigma-Aldrich) and 50% formamide (100%, Merk). 
To create single stranded DNA for the hybridization, the solution was incubated at 95°C for 
10 min and held on 72°C until transfer onto the micro arrays. 
 
 
3.14.2 Slides and hybridization 
 
Prior to hybridization the micro arrays were blocked for 30 min with a blocking solution 
containing 3M Urea (Merk), 0,1% SDS (20%, Sigma Aldrich) and water. Followed by a 
washing step for 5 minutes in wash solution II, which includes 0,1 x SSC (20x, Invitrogen) 
and 0,2% SDS (20% Sigma-Aldrich) in water. Slides were dried via centrifugation at 900 x g 
for 1 minute.  
Before applying the denatured DNA in 1 x hybridisation buffer onto the micro arrays, the 
slides and gasket chambers (Agilent) were pre-warmed to 72°C on a heating plate. 
Hybridization chambers (SureHyb, Agilent) were pre-warmed to 52°C in the DNA micro 
array hybridization oven (Agilent), which also assures a preheating of the hybridization oven 
to the required hybridization temperature of 52°C. The handling step for micro array 
hybridization was as follows: First we put a gasket chamber onto the hybridization chamber. 
Then one sample was loaded onto each of the three fields framed with a sealing ring. One 
glass slide containing 3 micro arrays, which were spotted in way that each array fits exactly 
into one sealing ring framed space, were put onto the gasket slide, which was loaded with 
110µl of denatured DNA in 1 x hybridisation buffer. The hybridization chamber was 
assembled and the thumbscrew of the chambers was tightened. Finally it was checked if there 
was only one air bubble per micro array, which can move around freely to mix the sample 
during the hybridization. The hybridization chambers were incubated in a rotary oven (DNA 
micro array hybridization oven, Agilent) for 16 hours at 52°C. After hybridization chambers 
 38
were disassembled and the gasket slides separated form the micro arrays in wash I solution 1 
1x SSC (20x, Invitrogen) and 0,2% SDS (20% Sigma-Aldrich). The gasket slides were 
washed for further usage and the wash I solution discarded. The micro arrays were placed in 
fresh wash solution I and washed for 5 min followed by 5 minutes in wash II and repeated 
dipping in wash III. Washings were performed in a colpin char, which was mixed by stirring. 
The slides were dried by centrifugation 1 min at 1000 x g 
 
 
 
3.14.3 Detection 
 
Detection of biotinylated hybridization products was obtained by streptavidin cy3 conjugate 
(Caltag Laboratories). The streptavidin cy3 conjugate was diluted 1: 400 in 1 x PBST buffer 
containing 1 x PBS plus 0,1% Tween (Sigma-Aldrich) and 1% milk powder bovine (Sucofin). 
80µl of this solution was pipetted onto a cover slip (24 x 60mm Marienfeld). The washed 
array then was carefully placed narrow above the cover slips in a way that the cover slips 
were attached to the glass slide via capillary forces of the PBST solution. The arrays were 
incubated with the detection solution for 30 min at room temperature protected from light. 
After incubation cover slips were removed from arrays in 1x PBST followed by a 5 min 
washing step in 1 x PBST and repeated dipping in MilliQ water. Slides were dried by 
centrifugation 1000 x g for 1 min and scanned on Gene Pix 4000A scanner (Axon 
Instruments).Cy3 signals were measured the micro arrays via exication at 532nm and 
emission was read at 560nm with a resolution of 10µm at a photomultiplier tube setting of 
700PMT. 
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4. Results: 
 
4.1 Optimization of cf serum DNA Isolation and genome wide 
enrichment of methylated DNA 
4.1.1 Isolation of cell free DNA from Serum 
 
To figure out the best serum DNA isolation strategy we compared four different approaches 
to isolate the cell free trace DNA amounts prevailing in human blood serum. For this test, sera 
of three healthy volunteers were isolated in triplicates in three independent experiments, at 
which every value of each triplicate was used for creation of the box plot and the calculation 
of medians and standard deviation. 
The ZR Serum DNA kit from Zymo, where the cell free DNA of the serum samples should 
bind to silica beads, did not work in our hands. Using the Blood midi kit form Qiagen, used 
widely in the respective literature for serum DNA preparation, we could obtain 7,51 ng 
DNA+/- 2,82ng (mean +/- s.d.) per ml of serum. Although the kit was easier to handle than 
the other silica membrane based isolation kit (Roche), the difference between the isolated 
DNA amounts was too big to legitimate the use of this less laborious kit.  
The MBD based isolation strategy, established during practical work before starting this 
master thesis resulted in a total DNA amount of 2,06 ng DNA +/-1,17 (mean +/-s.d.) per one 
ml serum. 
The optimized Roche isolation protocol resulted in 10. 31ng/ml +/- 4.13ng (mean +/- s.d.), 
which was the highest DNA level isolated from 1 ml serum in this experimental setup. To 
reach a reproducible high amount of extracted serum DNA the volumes of the aliquots per 
sample as well as the incubation times and temperatures were varied until the highest 
reproducible DNA yield was gained. 
These facts finally lead to the decision to use the Roche high pure template prepation kit to 
isolate all clinical serum samples from breast cancer patients and accordant normal controls to 
perform a methylation screen. 
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Fig.7: Boxplot of DNA amounts isolated 
from 1ml serum using different DNA 
purification kits or MBD based DNA 
isolation strategy. The sera of three healthy 
controls were isolated in triplicates. The 
DNA levels were measured with Pico Green. 
 
 
 
 
 
 
 
 
4.1.2 Evaluation of (silica and MBD based) DNA isolations for methylation testing 
 
At the analyses of the data obtained from different isolation strategies (figure 7) we addressed 
the question, why DNA levels prevailing in 1ml of serum were significantly lower using the 
MBD isolation approach than applying the membrane-based protocols (i.e. Quiagen or 
Roche). Therefore we hypothesized that this effect might be due to the higher affinity of the 
MBD protein for methylated DNA. 
In this tests it turned out, that applying the MBD for serum DNA isolation, on average 26,1% 
(P=0.0002 by student t-test) of the DNA levels gained with Roche High pure template 
preparation kit could be obtained from 1ml serum. The reason for this effect was investigated 
by qPCR tests on serum isolates using primers for the gene loci SALL3, HIC1, ESR1 and 
ZNF502. These tests were performed in an independent test series using sera of 12 healthy 
volunteers (age and sex matched). 
The differences between CT-values highlight the reduced amount of DNA, isolated with 
MBD except for ZNF502, which is methylated in healthy adults. Hence, there is no significant 
difference between the CT-values (i.e. DNA amounts) using the primer for ZNF502 for both 
extraction methods (Figure 8). We determined an average difference for CT-calls at 
unmethylated DNA fragments (i.e. SALL, ESR1, CHFR) of 2,81 by subtracting the CT calls 
form MBD isolated DNA from Roche isolated DNA. Doing the same calculation for 
methylated DNA fragments (i.e. ZNF502) a value of 0,09 was computed. These values were 
converted into percent values, which lead to the suggestion that in comparison to the overall 
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membrane based isolated DNA, 95% of methylated DNA fragments and 10% of 
unmethylated DNA fragments were isolated using the MBD procedure. 
Fig.8: Box plot of normal control DNA (n=12) isolated with MBD workflow or silica membrane based using 
primer for differential methylated DNA fragments The methylation status of the DNA fragments was ascertained 
on UCSC genome browser (http://genome.ucsc.edu/), whereas the amplified gene loci of SALL3, ESR1 and 
CHFR are unmethylated and the gene region amplified with ZNF502 is supposed to be heavily methylated in 
normal tissue. 
 
This significant enrichment of methylated DNA fitted perfect into our research field, where 
differences between methylation patterns of healthy persons versus breast cancer patients are 
shown, but the reduced amount of isolated DNA upon MBD-isolation (26% compared to 
Roche) made DNA manipulation and genome wide amplification very difficult. 
Based on several control PCRs results (data not shown) the MBD approach could not be used 
for accurate methylation studies without a methyl sensitive restriction digestion, which was 
due to the fact that a significant amount (10%) of the unmethylated DNA fraction was isolated 
from serum. In several experimental series for enrichment of the methylated DNA fraction, 
results were not consistent and enrichment was not only dependant on the methylation content 
when several DMRs were analysed, but rather being influenced by the neighbouring 
surrounding sequence context. 
Therefore this challenging method, where we started with the expression of the MBD protein 
in E.coli, purified the protein upon binding to nickel beads and then used these beads for 
serum DNA isolation was not implemented into our standard sample processing procedure. 
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4.1.3 Comparison of genome wide amplification systems 
 
When starting with trace DNA amounts prevailing in serum (figure 7, figure 13) the genome-
wide amplification of DNA samples became a key process of this work, providing sufficient 
amounts of DNA for methylation screenings. Therefore three different amplification systems 
were compared according their DNA yield and recovery of the methylation pattern after 
amplification, which was achieved by control PCRs. 
 
A 
1. RCA  2. APA-PCR   3. WGA 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Fig.9: (A) representative Gel images of whole genome amplification products using different approaches. In 
case of RCA (1) 2µl of the reaction volume were loaded onto the gel; for APA-PCR (2) and WGA (Sigma-
Aldrich) (3) 10µl of amplification reaction volume were loaded. (B) Means of DNA amounts yielded after 
various amplification reactions; error bars indicate the standard derivation. As input for each reaction served 
20ng of genomic DNA. 
  a     b    c      d           L    a   b  c    d   e  f               L  a   b   c   d   e    f   g   h 
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As template for these reaction served 50ng of genomic MCF7 DNA, which was treated 
according to the requirements of each method. These gel images gave first hints on the 
functioning and the performance of the diverse amplification methods. 
In contrast to PCR based adapter-mediated amplification (APA-PCR and the WGA from 
Sigma Aldrich), the RCA products are of high molecular weight. This is due to the 
amplification process, where circles in a range from 100bp to 1,5kb produced huge DNA 
molecules with consecutive repeats of the template circle. This isothermal reaction process 
resulted in high molecular weight DNA, which was observed in the region of 10kb and above. 
The PCR based adaptor mediated amplification resulted in amplified DNA fragments in a 
region of 200 to 800bp, a pattern that could be determined as typical for common PCR 
reactions, which highlights the basically differing process of the RCA to the PCR-based 
methods. 
The purified amplification reactions were measured for DNA content with Nanodrop. We 
observed big differences between these methods. Highest DNA amounts were measured after 
rolling circle amplification (RCA), where 15,7µg +/- 2,42µg (mean +/- s.d.) were detected. In 
case of the RCA the water controls (Figure 9, image A1, lane c and d) of the reaction showed 
products on the gel and we could detect 2,9µg DNA. 
The APA-PCR produced 2,68µg +/- 0,45µg (mean +/- s.d.) DNA and this amplification 
method showed a clear gel image without any contamination or products of side reactions, 
(Figure 9, image A2, lane e and f). On contrary to the WGA from Sigma, which showed 
throughout contaminated water controls (Figure 9, image A3, lane g and h), amounts of 4,5µg 
and more DNA were detected in these controls. These high amounts of unspecific amplified 
DNA or unknown side reactions lead to the exclusion of the WGA kit from further testing, 
although the DNA yield of 11,83µg +/- 2,2µg (mean +/- s.d.) was sufficient (Figure 9). 
 
To test whether the genomic DNA was amplified entirely or some parts of the genomic 
information got lost during the amplification process, we performed control PCRs on 
amplification products. Therefore 1µl of the purified amplification reaction served as template 
for the PCR reactions. 
The gel images (Figure 10) clarified, that information losses with both amplification methods, 
were existent. The positive controls, where unamplified MCF7 DNA served as template, 
showed 6 fragments (PitXa 315bp; contrA 240bp; Xist 200bp; contrB 175bp; RB1 138bp; 
SNRP 124bp). At the second positive control one fragment (RB1) got lost upon methyl 
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sensitive restriction digestion, but the remaining fragments should show up as product of each 
PCR reaction.  
This was not the case for neither of the two approaches for genome wide enrichment of 
methylated DNA, but apparently the RCA products contained more amplifiable fragments for 
succeeding PCR reactions.  
We concluded from these observations that the rolling circle amplification had the 
disadvantage of contaminated negative controls, but had two big advantages over the APA-
PCR. On the one hand about six times higher DNA yields were observed, and on the other 
hand a more reliable representation of the methylation-pattern after the amplification step was 
achieved. 
 
RCA products     APA-PCR products 
 L      +     +    1     2     3    4     5      6   7    ad     L       L      8    9     10     11   12    13     14   15  ad      L 
 
 
 
 
 
 
 
 
Fig.10: Control PCR with genome wide amplified DNA to assume the DNA recovery. L = ladder; + = positive 
control: first lane undigested 2nd lane methyl sensitive digested MCF7 DNA both without previous amplification. 
Lanes 1 – 15 methyl sensitive digested MCF7 DNA, which served as template for each genome wide 
amplification strategy, ad = water control of amplification reaction 
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4.2 Sample preparation for methylation screening in serum of 
breast cancer patients 
4.2.1 Serum processing workflow 
 
 Working process     DNA status 
1. DNA Isolation     
 
Roche High pure template     
Preparation kit        
 
 
2. Creation of sticky ends 
 
Restriction digestion with 
FspBI (creates AT overhangs) 
 
 
3. Circularisation of DNA molecules 
 
T4-Ligation 
 Selfligation enabled upon sample dilution (1ng/µl DNA- 
Concentration) 
 
 
4. Methyl sensitive restriction digestion 
 
HpaII, Hin6I, AciI and Hpych4IV 
were blocked by mCpG 
 
 
 
5. Rolling circle amplification (RCA) 
 
Enabled by strand displacement activity 
of Phi 29 
 
 
 
6. Multiplex-PCR 
 
Specific amplification of 360 target fragments 
per sample by PCR 
 
 
 
Fig.11: Serum processing workflow. Images for this figure were adapted form the publications of (Dean et al., 
2002) and (Wang et al., 2004) and modified as required. 
 46
The work with clinical samples and normal controls followed a strict processing scheme. The 
samples were randomized after the DNA isolation process and this random order kept until 
hybridization on the micro arrays. All samples and controls described in the following part 
were isolated and further processed in one experimental run to minimize experimental 
variances. 
The collective of 96 samples (i.e. clinical samples, normal controls and assay controls) were 
treated in the way outlined in the serum processing workflow (Figure 11). Control PCRs were 
performed before and after rolling circle amplification, as well as diverse argarose-gels after 
control PCRs, RCA and Multiplex-PCR (not shown in the workflow graph). 
 
4.2.2 Patients information and study groups 
 
Overview basic patient information 
 
Study group  histological finding   estrogenic Rec. pos pN >0  
 
   G1 G2 G3 other 
 
M1    1 3 2   3  4 
 
 
Relapse  2 3     3  2 
 
 
G3     6    6  2 
 
 
G2    6     5  3 
 
 
G1   6      6  2 
 
 
C.I.S   1 4 2    6  0 
 
 
Benign    12    0  0 
 
 
BRCA1/2        0  0 
 
 
 
Tab.4: The histological grading (G1-G3) refers to the affection of tumor surrounding tissue of the invasive 
lobular or ductal tumors. Estrogenic receptor tests are included in standard breast cancer diagnoses process and 
serve as additional indication. pN staging ≥ 0 shows a local affection of lymph nodes. 
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The investigated samples were selected from a collective of clinical samples obtained at initial 
diagnoses and provided by Prof. T. Wagne from AKH Vienna. On the basis of supplied 
clinical data form the hospital the patient samples were divided into test groups, to allow 
addressing of distinct questions, which were expected to be answered upon this test series. 
The 8 study groups were then named according to their clinical representation. M1 samples 
were derived form patient with a metastasizing tumor. The relapse group resembled patient 
sera, where the malign neoplasm raised again in a time period of 5 years after the first 
treatment. The group identifier G1-G3 was according to the histological grading. 
C.I.S. indicates a carcinoma in situ, where an epithelial tumor was diagnosed, without 
growing invasively. The group of benign tumor samples was collected from patients with 
fibro adenomas, which did not affect-surrounding tissue. The term BRCA1 or 2 refers to 
patients with hereditary breast cancer bearing a germ-line-mutation in one of these two genes.  
 
 
4.2.3 Measurement of trace DNA amounts 
 
For measurement of small DNA amounts like prevailing in blood serum we developed an 
adjusted protocol of the “Quant it” Pico Green kit from Invitrogen. Therefore we reduced the 
assay volume from 1ml to 100µl, which enabled us to measure the DNA concentration of 5µl 
sample diluted in 95µl working solution. Then the values were calculated for the entire 
sample volume of 55µl. 
The lambda DNA dilutions, serving as standard, were prepared in a volume of 50µl and 
ranged from 7,8pg/µl to 250pg/µl (Figure 12). This principle enables exact DNA 
concentration measurements of the low amounts of DNA extracted from the serum samples 
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Fig.10: DNA standard curve for Pico Green-DNA measurements: All reagents including the lambda-DNA 
dilution of the assay were freshly prepared for every measurement. 
 
 
4.2.4 Cell free DNA derived form patients and controls 
 
DNA from serum samples (800µl) was isolated using the optimized Roche protocol. Figure 
13 shows an increased level of serum DNA in breast cancer patients with a metastasizing 
etiopathology, which illustrated one of the key findings of this work. We detected 45,64 ng/ml 
+/- 32,31ng (mean +/- s.d.) in the serum of patients with a metastasizing disease in contrast to 
8 ng/ml +/- 5,48ng (mean +/- s.d.) for patient with a solid tumor of grading G3. 
9,86 ng/ml +/- 11,4ng (mean +/- s.d.) were detected for benign cancers and 10,58 ng/ml +/- 
9,71ng (mean +/- s.d.) for normal controls. These DNA concentrations are shown in the box 
plots, which enhanced the hypothesis that there is only an increase of serum DNA from 
patients with a metastasizing disease. 
As reported in current literature about 60% of patients with metastasizing cancer show a 
significant increase of cell free serum DNA. This was the case in our study too, but the height 
of the 60% of serum isolates with increased DNA levels lead to a significant increase of the 
entire group of M1 patients. Hence the conclusion out of these observations was a significant 
increase of serum DNA levels only for the M1 study group. 
Further there was no increased DNA level in study group G1-G3 or in the serum of patients 
with benign cancers as claimed in some recent reports.  
Conc. in pg/µl Value 
250 10543 
125 5080 
62,5 2642 
31,25 1395 
15,6 699 
7,8 419 
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A slight higher median of 23,46 ng/µl +/- 13,48ng (median +/- s.d.) was observed in the group 
of patients with a new arising of their cancer (i.e. Relapse). The reason for this observation 
was not cleared entirely, because of absent patient information a few years after blood 
donation. We do not know if some of these patients developed neoplasm on other sites of their 
body. Anyway we could not distinguish between these two groups (i.e. M1 and Relapse) 
because of a P-value of P = 0,45 (by Wilcox rang sum test). 
Hence we excluded this sample cohort for the calculation of P-values. Between study group 
M1 and the other groups the DNA amounts differed significantly by a P value of 0,0013 (by 
Wilcox rang sum test). Further the P value was computed for discrimination between the M1 
group and each study group, whereupon P < 0,005 (Wilcox rang sum test) were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11: Box plots of extracted DNA per 1ml human blood serum. Each study group consisted of at least 6 
serum samples or more. The abbreviations (i.e. M1, G1-3, etc) refer to the study groups as outlined in the section 
patient information and study groups (table 4). WT applies to the group of normal controls (n=24). 
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4.2.5 Evaluation of sample quality and methylation sensitive restriction digestion 
 
Ancillary to concentration measurements and separation by gel electrophoreses to control 
amplification, the control PCRs were the main measures to monitor the DNA samples during 
manipulation and amplification in our experimental procedure. The first control PCR in our 
assay was performed after methyl sensitive restriction digestion(figure 11, step 4). 
On basis of the number of amplified PCR fragments we could evaluate the sample quality. So 
the more fragments per sample were detected, the better was the sample quality and the more 
complete was the genomic DNA of each sample. 
The second information provided by this PCR, gave insight into the restriction digestion. The 
two positive controls in Figure 14 represent a complete methylation sensitive restriction 
digestion. First lane displays an undigested PCR-reaction of normal DNA, the second lane a 
digested one, at which the fragments with a length of 315bp (i.e. PitXa) and a length of 138bp 
(i.e. RB1) are not present, because they are known to be unmethylated in healthy blood DNA. 
Therefore complete digested samples had to show four fragments as the second positive 
control. In this case it was assured that the restriction digestion was complete and the sample 
quality was high. Figure 14 shows that all samples shown here had underwent a complete 
methyl sensitive restriction digestion and all remaining possible fragments were amplified.  
In Gel 1 (lane a-p) amplicons of clinical serum samples of any kind were loaded (e.g. a refers 
to sample P300 of the Relapse group or p refers to sample WT181 of the normal control 
group), at which 1µl of extracted DNA served as template for the PCR reaction. From all 
samples the expected number of fragments were amplified. At lane h and q water controls 
were loaded and in lane m an operator mistake occurred and the sample was loaded again onto 
another gel. 
Gel 2 (right section of figure 14) shows two water controls, in this case the two water controls 
(i.e. d and p) passed through all steps like the clinical DNA samples. The last lane was again 
reserved for the water control of the PCR reaction.  
A close view on gel 2 (right section of figure 14) reveals an additional fragment of the 
samples j-o. These PCR products originated from assay positive controls, where 50ng of 
MCF7 DNA was processed. These controls were treated parallel to the clinical samples. 
MCF7 DNA is derived from a breast cancer cell line, at which the PitX2 locus is methylated. 
Hence there was no digestion of the PitX-DNA fragment by the methyl sensitive restriction 
digestion.
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Fig.14: Chosen control PCRs of serum isolates and controls after ligation reaction and before genome wide 
amplification. L refers to the 100bp-ladder. The lanes marked with + are positive controls, at which the second is 
methyl sensitive digested. The abbreviations a-q of each gel refers to samples; assay controls (right section: j-o) 
and water controls (left section: h, q; right section d, p, q). PCR products: PitX (314bp); contrA (240bp); Xist 
(196bp); contrB (174bp); RB (138bp); SNRP (124bp). 
 
 
4.2.6 Rolling circle amplification 
 
An accurate executed RCA reaction was ascertained by two independent controls. Therefore 
directly after the reaction an aliquot of 1µl (approx. 500ng) was loaded onto a gel. As outlined 
in the pre-test section of this work and shown in figure 15, the reaction created DNA 
molecules of high molecular weight. The image also indicates the DNA amounts yielded by 
this reaction, which were about 15µg for each 30µl reaction. 
Figure 15 shows representative RCA-amplicons, for example, c refers to sample P23 of the 
study group M1 and m refers to WT212 of the normal control group. The RCA product of a 
water control was loaded onto lane i. Here one could assume large DNA amounts produced 
by the reaction, which was confirmed upon Nanodrop measurement, where we determined 
7.9µg in the whole reaction, which was previously purified as outlined in the methods section. 
Despite this high DNA concentration a significant contamination of this water control was not 
detected in the second control PCR (Figure 16: left section, sample o). 
In lane o (figure 15) a normal control sample was loaded. In this case the expected small 
DNA amount was not verified on Nanodrop, where 18,5 µg DNA was determined in the 
purified reaction plus a positive result of the second control PCR. 
The box plots section in Figure 15 gives an overview of the DNA yield after genome wide 
amplification. We expected same DNA amounts for all study groups and samples, which was 
not the case in our experimental setting. 
The plot represents a cohort of samples where the RCA worked well, which was observed in 
study group M1, Relapse, BRCA and WT. 
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So we assumed throughout complete RCA reactions for these samples. The fact that some 
researchers reported that they could amplify only every second serum DNA isolate upon 
RCA, makes a definite analyses of the diverse DNA amounts and their associated serum 
samples difficult. Although 10% of the samples showed an incomplete RCA reaction, 
analysed upon concentration measurements, gel images and multiplex-PCR yield, all samples 
were further processed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15: Rolling circle amplification. Box plot of obtained DNA amounts after RCA of the different breast 
cancer study groups. Beneath a representative gel image of 1µl rolling circle reaction loaded onto a 2% agarose-
gel. In the lane marked with L 100bp ladder was loaded. The labels a-p refers to diverse samples and controls. 
  L       a        b        c         d         e       f        g       h         i         j         k        l        m       n        o         p 
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4.2.7 Evaluation of enrichment of methylated DNA upon RCA 
 
In order to get an impression whether the enrichment of methylated DNA was successful or 
not we performed control-PCRs on the RCA amplicons using the same 6 primer pairs as for 
the first control-PCR (figure 14). 
These representative gel images follow the same pattern as the gels loaded with amplicons of 
the first control PCR (figure14). The ladder is followed by two positive controls, at which the 
first shows untreated genomic normal control DNA and second PCR was performed with a 
methyl sensitive digested DNA template, both controls did not undergo the RCA. 
In the left section of figure 16 clinical samples are shown except for sample a, which is 
genomic unamplified MCF7 DNA as well as sample c in the right section of figure 16, where 
the PCR reaction did not work. Both samples served as positive control of the following 
multiplex PCR.  
The control PCR water controls were loaded onto lane p in the left section and the right 
section. Another water control, which was included into the assay at the initial isolation 
process, was loaded onto lane o in left section of figure 16. 
Provided that the control PCR should result in 4 PCR products and bearing in mind that 
complex genomic/chromosomal aberrations are common to cancer cells of which the cell free 
serum DNA might have derived, we could assume that the whole genome amplification 
worked sufficiently well (e.g. right section, lanes i-k).  
We observed that the RCA did not produce such sufficient results for all samples. Many 
samples like f and g in the right section of figure 16 were amplified incomplete, which could 
be deduced from incomplete band patterns or too weak gel bands. This suggested that the 
templates for this PCR reaction were not equally amplified by the genome wide amplification. 
The combination of these three gel images (Fig. 14, 15, 16), which were created for each 
processed sample, enabled us to evaluate the experimental course of every sample. For 
example one may track the sample WT213, which was loaded on left section in figure 14 in 
lane n, further in figure 15 in lane n and finally it was shown in Figure 16 in lane l on the right 
section. 
For the example of WT213 the experimental course could be rated as satisfying, because the 
first control PCR suggested a complete methyl sensitive restriction digestion and a good 
sample quality. The control gel of the RCA suggested a huge amount of DNA, which was 
confirmed by a Nanodrop measurement of 18,64µg DNA. Finally control PCR 2 indicated an 
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almost complete amplification of the DNA isolated form serum, because three of four strong 
bands are visible on gel 2 (lane l).  
This process could be followed for each sample in our assay and was used in combination 
with concentration measurements to confirm the accuracy of sample manipulation.  
 
 
 
 
 
 
 
 
 
Fig. 16: Representative gel image of the second control PCR. The reaction was performed with genome wide 
amplified DNA samples. The abbreviations a-q of each gel refers to samples assay controls (left section: c; right 
section: h) and water controls (left section: o, q; right section c, q). PCR products: PitX (314bp); contrA (240bp); 
Xist (196bp); contrB (174bp); RB (138bp); SNRP (124bp). 
 
 
4.2.8 Multiplex-PCR control 
 
As outlined in the methods section we performed a multiplex-PCR consisting of 12 reactions 
with 16-24 primer pairs each to create a suitable amplicon for the target micro array. To 
assure an accurate activity of the PCR-reaction 10µl of pooled amplicon were loaded onto a 
2% agarose gel. 
Noticeable in Figure 17 are the strong blazing gel bands in a range smaller than 100bp, which 
originate from primer dimers of the multiplex PCR reaction. Primers are available in the PCR 
reaction in excess and therefore give such a huge gel band. 
Thus 50µl of this unpurified reaction were used for micro array hybridization, as outlined in 
the materials and methods section of this work.  
The weak bands in the range of 200bp indicate specific products derived from CpG360-PCR, 
which should amplify 360 targets. This would indicate that the RCA bare enrichment of 
methylated DNA. 
The gel image analyses were also used for a last validation of the samples before micro array 
hybridization. In this connection we could control if the sample was amplified accurately and 
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had a closer view on samples that provided small DNA yields like on this gel sample P114 
from sample group M1 (figure 17, lane p). 
In this case, the course of the sample from first PCR (figure 14, sample f, left section) upon 
RCA (figure 15, sample f) and second PCR, where we detected three strong bands (data not 
shown), was promising, but the multiplex control gel seems to show very little products. 
Exclusion or any other final conclusion by means of the gel images in this section would not 
have been meaningful. 
 
 
 
 
 
 
 
Fig.17: Gel image of the pooled CpG 360-multiplex PCR control gel. Pooled amplicons (10µl) of each sample 
were loaded. L refers to the 100bp ladder. In lane an assay water control was loaded (Same control is shown in 
lane o in Fig.9 and Fig.10 gel 1), the rest of the lanes were loaded with amplicons of clinical samples. 
 
 
4.2.9 Hybridization process 
 
After micro array hybridisation and detection, an accurate function of these processes was 
assured via control of the scanned images (figure 18). On basis of the signal intensity of each 
spot a data file was created by the GenPix software. The values were further log2 
transformed, a median was created out of the probe replicates, and then the data were used for 
analyses. 
 
 
 
 
 
 
 
Fig.18: Representative images of scanned micro arrays. The left micro array is derived from a normal control 
sample. The right one originates from a sample of the study group M1. 
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4.3 Analyses of the CpG360-micro array data 
 
4.3.1 Normalization 
 
To identify new methylation markers in the serum of breast cancer patients, we first had to 
assure that all array data could be compared to each other without being influenced by any 
experimental effect or methodological failure.  
So, if an array did not show at least two times the median signal intensity of the water control 
it was excluded form further analyses. Concretely that means (Figure 19), if an array showed 
an overall signal intensity below 11 it was excluded form the analyses. Therefore the data had 
to be normalized 
 
Overview of samples used for data analyses 
 
Study group  
 DNA isolation Analysed excluded in % 
 
M1 6 5 17 
 
Relapse 6 6 0 
 
G3 6 5 17 
 
G2 6 5 17 
 
G1 6 6 0 
 
C.I.S 6 6 0 
 
Benign 12 12 0 
 
BRCA1/2 10 9 10 
 
WT 24 19 21 
 
Total 82 72 12 
 
 
Tab.5: DNA isolation reflects the number of samples, which were processed in this assay according to table 4. 
Number of analysed samples represents samples that were successful manipulated and amplified. Excluded in % 
indicates the fraction of samples per study group, which were excluded from methylation screening. 
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All water and positive controls were excluded before normalization and the clinical relevant 
samples were normalized using gene-by-gene median normalization from the software 
package BRB array tools for Microsoft Excel (Simon et al., 2007).  
Box plots of different representative samples before and after normalisation are shown in 
figure 19. The box plot shows comparable signal intensities derived from different patient 
groups. After normalization, not all samples did reveal the same median, which is due to the 
gene-by-gene normalization strategy.  
The median normalization of BRB array tools first selected a reference array according to 
certain selection parameters, at which the median log intensity should equal the overall 
median of all arrays. Then, a gene-by-gene difference between each array and the reference 
array was computed. This median difference of each array and the reference array was then 
subtracted from the normalized arrays, in a way that the gene-by-gene difference between the 
normalized array and the reference array became zero. 
Further a gene was filtered out, if more than 50% of the sample values from one probe were 
absent. 
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Fig.19: Box plots of log (2) values from signal intensities after DNA hybridization from chosen samples before 
(A) and after (B) gene-by-gene median normalization, which were grouped by their study group. Representative 
selected C1 and C2 refer to assay controls; WT data were taken from representative normal controls; M1, RE 
and G3 refer to their study group label. 
A 
B 
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4.3.2 Reproducibility of targeted methylation screen 
 
An accurate multiplex PCR and hybridization process was ensured by insertion of twice the 
same sample at the experimental stage of the CpG360 multiplex PCR. In other words the 
RCA product of the samples P114 and P43 were randomly allocated into the multiplex 
amplification and hybridized on different arrays. 
By means of this high correlation of r = 0,924 and r = 0,912 for the samples P114 and P43 
respectively we could exclude that the following discrimination between diverse cancer 
samples and normal controls was due to PCR bias or variations in the hybridization process. 
These correlations also confirms the reproducibility of this multiplexing strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.20: Correlation of normalized values of replicate samples. Sample P114 originates from the study group 
M1, whereas sample P43 is part of the study group benign breast cancer samples. 
 
 
4.3.3 Assay controls 
 
To ascertain the accuracy of the sample data we implemented triplicate samples of MCF7 and 
normal control DNA as well as negative controls in the experimental setup, which will be 
discussed in the following section. 
The dendrogram in Figure 21 displays the assay controls, which illustrate on the one hand, the 
discrimination of MCF7 tumor cell line versus normal DNA of the multiplex PCR followed 
by the detection of the PCR fragments on the micro array, and on the other hand again assure 
a correct function of the CpG 360 assay. 
Figure 21 provides an overview of positive controls in our assay (i.e. normal DNA isolated 
from whole blood of healthy adults and MCF7 cell line DNA), which enabled the 
discrimination between MCF7 breast cancer DNA and wild type DNA. This should show the 
optimal experimental setup for the multiplex PCR procedure, at which the DNA sample was 
not genome wide amplified and therefore the DNA has an optimum DNA quality for analyses.  
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The dendrogram was created in BRB array tools and compares the pair wise similarities of 
amplified PCR products from each sample. In this way, clusters of similar genes are created. 
Then the clusters were compared to each other, calculating a Pearson correlation, at which 
finally, one minus the Pearson correlation serves as metric distance between the samples as 
shown in Figure 21. (e.g. distance in the dendrogram between control MCF7 A and MCF B). 
In other words, we observed correlations between MCF7 replicates of r = 0,89 and between 
wild type DNA replicates a correlation of 0,88 was determined, being a measure for the entire 
procedure enrichment of methylated DNA. 
Via the class comparison tool from the BRB array tools package, a calculation algorithm 
described in detail in the section “Discrimination between study group M1 and normal 
controls”, we could determine 24 significant genes with a P-value of P < 0,005, which 
allowed the discrimination between breast cancer DNA and wild type DNA. 
These introductory examples confirmed the accuracy and reproducibility of this method as 
well as a prove of the suitability of this detection tool. After checking the performance of our 
test by analyses of several controls, we started data analyses for elucidation of methylation 
markers in serum of breast cancer patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.21: Performance testing of the CpG369 assay. Controls were gene-by-gene median normalized. Triplicates 
of the methyl sensitive digested DNA from MCF7 cell line or genomic wild type DNA were amplified and read 
out upon micro array hybridization without previous genome wide amplification. 
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4.3.4 Discrimination between study group M1 and normal controls 
 
The CpG360-data analysis of the clinical samples started with the attempt to distinguish 
between patients with metastasizing cancer and normal controls. Due to the elevated serum 
DNA levels this strategy seemed most plausible, because the most significant difference were 
expected between these two groups. 
Therefore, we performed cluster analyses of the two classes. This analyses may not always be 
biological meaningful, because all genes, which pass the filtering criteria, were included into 
analyses. As shown in Figure 22, two main clusters emerged in the dendrogram, which could 
be allocated to the two different study groups. One outlier was observed, namely sample 
WT181. This artefact could be explained, by having a look on the experimental course of the 
sample. Although we extracted a rather high amount of 35ng of DNA from the serum of 
sample 181 there were only about 9µg of DNA detected after genome wide amplification, 
which indicates low performance of the RCA reaction. In addition, the median signal intensity 
on the micro array was 9,8 (log (2) of the absolute value), which is distinct from other 
samples, and should be excluded from further analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.22: Cluster analyses of normal controls (indicated as “WT_” and “norm”) and study group M1. Samples 
form the distinct groups are clustered. Two M1 samples (i.e. P23 and P114) show a correlation of r = 0.88, just 
like two WT samples (i.e. WT213 and WT 189) that show a correlation of 0.92. In contrast to that, two samples 
of different groups (i.e. P21 and WT213) show a correlation of 0,74. 
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As next step of our array data analysis we performed class comparisons between the two 
study groups (M1 versus WT), using BRB array tools. This calculation applies a two-sample 
t-test for each gene on the normalized log intensities of the DNA samples by comparing the 
values among the groups. Further, a univariante permutations test estimating the false 
discovery rate of each gene was computed. The method of Benjamini and Hochberg was 
applied for this calculation (Benjamini et al., 2001). 
The negative log (10) value of the P-value is plotted in Figure 23. For the creation of the plot 
(Figure 23) all significant genes at P < 0.1 are shown. Because of this minimal stringent 
application all false positive were displayed. This plot should just reflect the large number of 
genes, which are statistically significant but did not support discrimination between the study 
groups. 
The genes, which lead to the separation of the array data into two groups, are highlighted red. 
These genes were chosen on the basis of the P-value, median log intensity, fold changes 
between the study groups and their false discovery rate. During analyses no genes with a false 
discovery above 5% were accepted and we did not mandatory select the genes with the 
highest P-values. The median signal intensities of the suggested significant genes were 
controlled first. This was done to exclude genes, which were differentially positive or 
negative. If a gene had a median log intensity of 13 in the WT group and a median intensity of 
15 in group M1, the gene was maintained as significant although both values are clearly 
positive and indicating a successful amplification of the fragment in both study groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.23: Negative log (10) value of P-values derived form two sample t-tests for all genes on the micro array in 
alphabetical order. Thus the higher the value in the plot the smaller is the concordant P-value. 
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Result of class comparison analysis from the 8 selected genes 
 
Gene name   Signal intensity Signal intensity 
 P-Value FDR of M1 samples  of WT samples 
 
BOLL <0,0005 <0,0005 15,8 10,1 
 
SRGN <0,0005 0,0006 15,7 5,3 
 
CLDN1 <0,0005 <0,0005 15,7 11,1 
 
ZNF711 <0,0005 0,003 14,7 5,8 
 
CD24 <0,0005 0,004 13,4 6,5 
 
DCC 0,002 0,04 11,9 9,5 
 
KLF4 0.0005 0,01 10,5 11,5 
 
TMEFF 0,004 0,04 12,3 9,8 
 
 
Tab.6: Genes plus values, which lead to the selection of this marker set. FDR refers to the false discovery rate. 
The signal intensity of the two study groups reflects the median log (2) value of each gene for all samples of one 
study group. 
 
Before we started our attempts to classify the other study groups (i.e. Relapse, G3, G2, G1, 
C.I.S., Benign and BRCA 1/2) by means of the 8 significant genes that enabled a separation 
of study group M1 and normal controls, we searched for genes that differ in their methylation 
profile between each study group and normal controls. We also checked if we could find 
genes that were differentially methylated in the specific study groups. These analyses were 
performed in the same manner as the search for significant genes in study group M1 via a 
two-sample t-test for each gene. This analysis approach did not elucidate marker for 
discrimination of the study groups. Therefore our further analysis was focused on the 8 
selected genes (table 6), which enabled discrimination of M1 vs. WT samples. Before further 
statistical analyses, we had a closer view on the percentage of positive signals of each study 
group based on the introduction of a cut off value of 11 (table 7) as well as the percentage of 
positive signals matched to patient information (table 9). 
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Overview of positive signals in percent of each study group for 8 genes according table 6. 
 
Study group Gene names 
 
 BOLL CD24 CLDN1 DCC KLF4 SRGN TMEFF2 ZNF711 Σ 
 
WT 10,53% 21,05% 15,79% 5,26% 84,21% 15,79% 0,0% 15,79% 12,5% 
(n=19) 
 
M1 100% 100% 100% 80% 0,0% 100% 80% 100% 95% 
(n=5) 
 
Relapse 66,6% 66,6% 83,3% 50% 0.0% 66,6% 66,6% 66,6% 70,8% 
(n=6) 
 
G3 20% 60% 20% 0,0% 60% 60% 20% 40% 32,5% 
(n=5) 
 
G2 40% 20% 20% 40% 60% 60% 20% 40% 37,5% 
(n=5) 
 
G1 50% 33,3% 66,7% 33,3% 66,6% 33,3% 33,3% 33,3% 43,4% 
(n=6) 
 
C.I.S 16,6% 16,6% 16,6% 66,6% 83,3% 33,3% 16,6% 16,6% 24,8% 
(n=6) 
 
Benign 18,2% 18,2% 9,1% 18,1% 63,3% 9,1% 9,1% 18,2% 17,1% 
(n=11) 
 
BRCA1/2 44,4% 33,3% 33,3% 33,3% 66,6% 33,3% 22,2% 22,2% 
(n=9) 
 
Tab.7: Percentage of positive signals per study group per gene. 
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Median log (2) signal intensity of selected genes according to study groups 
 
Study group Gene names 
 
 BOLL CD24 CLDN1 DCC KLF4 SRGN TMEFF2 ZNF711 
 
WT 9,9 4,3 10,7 10,1 11,6 3,7 10.1 3,7 
(n=19) 
 
M1 15,9 13,3 15,7 12,1 10,5 15,9 12,7 14,7 
(n=5) 
 
Relapse 15,4 12,6 15,3 11,5 10,6 15,4 12,4 14,3 
(n=6) 
 
G3 9,8 11,4 10,6 10,6 11,6 15,3 10,3 10,4 
(n=5) 
 
G2 10,6 3,7 10,4 10,6 11,4 14,32 10,2 3,7 
(n=5) 
 
G1 12,2 10,9 15 10,5 11,3 4,6 10,3 6,7 
(n=6) 
 
C.I.S 10 6,6 10,5 11,2 11,4 5,2 10,4 3,4 
(n=6) 
 
Benign 9,9 4,1 10,6 10,5 11,3 3,7 10,1 3,7 
(n=11) 
 
BRCA1/2 10,4 9,6 10,3 10,8 11,1 4,1 10,4 3,8 
(n=9) 
 
Tab.8: The median signal from all arrays of one study group was calculated for each gene.  
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Overview of positive signals in percent of 8 genes matched with different clinical information 
 
Clinical information Gene names 
 
 BOLL CD24 CLDN1 DCC KLF4 SRGN TMEFF2 ZNF711 Σ 
 
Hysterectomy 60% 40% 50% 60% 50% 50% 50% 50% 51,2% 
(n=10) 
 
Lymph nodes 61,5% 46,2% 53,9% 38,5% 38,5% 46,2% 38,5% 46,2% 46,1% 
(n=13) 
 
E.R.+ 50% 56,2% 62,5% 56,6% 43,8% 62,5%q 50% 50% 53,8% 
(n=16) 
 
E.R.+/- 28,6% 28,6% 14,35 28,6% 57,1% 42,9% 14,3% 28,6% 30,3% 
(n=7) 
 
P.R. + 20% 40% 20% 40% 80% 40% 20% 20% 35% 
(n=5) 
 
P.R.+/- 30% 30% 60% 30% 50% 30% 30% 30% 36,3% 
(n=10) 
 
Tab.9: The assessment of positive signals according to clinical markers did not reveal a significant elevation of positive signals of any gene for a 
specific clinical marker. The term Lymph nodes refers to confirmation of affected Lymph nodes of these patients. In other words these patients had local 
lymph node metastases. Estrogenic rec.+ implies that these patients had a strong positive detection of estrogenic receptors. Whereas E.R. +/- implies a 
moderate detection. This notation is valid for progesterone receptors as well 
.
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4.3.5 Discrimination between all study groups 
 
Table 7 and table 8 give an overview of positives and signal intensities of 8 selected genes 
according to sample groups and clinical presentation. Keeping in mind that more than one 
false positive value increased the log value of median signal intensity, one can estimate the 
difference between the median values of study groups with differential methylated genes.  
To make the calculated values in table 7 and 9 easier to interpret, we will briefly discuss one 
example. We compared the signals of the CLDN1 probe from WT to the M1 study group. In 
the M1 study group 100% of the samples were positive for CLDN1 obtaining a log value of 
the median signal intensity of 15.7. The log value of the median signal of CLDN1 from the 
WT group is 9.9, which does not imply that the difference between a positive CLDN1 signal 
and a negative one was 5.8, because in the WT group 15,6% of all arrays gave a positive 
signal (i.e. three arrays), when we recalculate the median signal intensity of the WT samples 
for CLDN1 without these three arrays a median log intensity of 9,5 is observed for this gene 
in this study group. This example also shows that the cut off value of 11 was rather used to 
rate gene signals positive than negative. 
Particularly table 7 shows the result of this assay. One can see that the M1 group, which 
showed 100% of the expected signals for 6 out of 8 markers, can be clearly differentiated 
from the WT group, where 6 out of 8 marker showed fewer than 20% false positives, as well 
as from all other study groups. In the M1 study group all genes, except KL4, provided a clear 
positive signal for the selected genes. In contrast to that, the signals of these genes were 
overall negative in the WT samples. The methylation status of the gene KL4 seemed to be the 
other way round. Here we observed negative signals in the study group “M1” and “Relapse” 
and positive signals in the normal controls. Analysing the values of each candidate marker in 
table 7 and 8 concerning the difference of the median log intensities between the study groups 
and the number of false positive signals per candidate marker one could determine a ranking 
of the gene markers with most biological meaning and best discrimination between groups, 
which starts with SRGN followed by ZNF711, BOLL and CD24. This ranking of significant 
genes was confirmed partially by statistic test in the section “4.3.6. Statistical analyses”. 
These tables further highlight the prognostic potential of the gene SRGN, since high median 
log intensities were observed also in study group G3 and G2. Therefore the SRGN marker 
was considered as the most promising candidate marker of our assay. On the one hand, big 
differences in the median log intensities were observed, which indicates a biologic meaningful 
observation, and on the other hand, a promising course of the methylation status of this gene 
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can be assumed, because increasing positive signals could be observed with rising severity of 
the illness. 
Despite this positive outcome of our experiments, results have shown that a distinct 
discrimination between the normal control group and “Benign”, “C.I.S”, “BRCA1/2” and 
“G1” was not possible and the differences between normal controls and study group G2 and 
G3 were rather small. It should be mentioned further that due to incomplete patient 
information the BRCA1/2 group might consist of healthy individuals, which had no tumor at 
time of blood donation, and patients with tumors of undefined grade. Because of this 
inaccuracy, we had to split the group into healthy patient and patients with breast cancer of 
undefined grade, which made the study group to small for a meaningful analysis. 
The 66% of positive signal of the candidate marker gene DCC in study group C.I.S is still 
under investigation, because on basis of these experiments we could not predict whether this 
observation was due to false positive results or a biological reason. 
The evaluation of the array data was continued by matching the positive or negative signals of 
the selected genes to the clinical information of the diverse patients (table 9). To establish a 
connection between the clinical features and our results, the array data were grouped 
according to this information. The organisations of the samples in study groups were broke up 
for this analyses approach. We observed a superior number of positive median signal 
intensities from patients, who underwent a hysterectomy, for all genes analysed. Higher 
numbers of positive signals of the selected genes were confirmed at a strong positive 
estrogenic receptor throughout the study cohort. Further analyses of the patient information 
like lymph node metastases, strong or moderate positive progesterone or estrogene receptors 
did not provide a significant increased or decreased levels of positive signals for the 8 
analysed genes. 
Figure 25 should give an insight into our decision to create a test set consisting of study group 
M1 and normal controls and a following evaluation process with all study groups. This plot of 
negative log (10) P-values (Figure 25) was created in the exact same way as the plot in Figure 
23 and it shows clearly that the selected significant genes vanish in the surrounding P-values 
of genes with no biological meaning. 
Finally we want to point out that a determination of significant genes, upon analyses of all 
samples at once, is more complicated and more error-prone than a division into two 
evaluation steps for elucidating markers, which are suitable to distinguish between study 
groups. 
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In figure 25 a throughout decrease of all P-values can be observed. This fact reflects also the 
restricted possibility to distinguish between groups as discussed above and shown in table 7 
and table 8. Although there is a significant difference between normal controls and study 
group M1 and relapse, and the assumption that on basis of SRGN methylation also tumors of 
Grade 2 and 3 can be verified, this would have been difficult to figure out if we started our 
analyses with all samples at once. Figure 25 should also indicate that for the analyses of 
serum samples a two step analyses approach, where first exclusively sera of patients with 
metastasizing breast cancer and normal controls were analysed, is more suitable than an 
analyses of all available samples at once. 
On basis of table 7 and 8 we considered if the study groups C.I.S and benign tumors should 
rather be rated as a wild type serum sample than a cancer sample. In other words we kept in 
mind that possibly only invasive malign neoplasms can be detected by methylation-markers in 
patient serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.25: Negative log (10) value of P-values derived form two sample t-test for all genes on the micro array in 
alphabetical order. Values were computed, including all samples of all study groups into the calculation 
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4.3.6 Class prediction 
 
The nearest neighbour prediction is another common method to classify array data. This 
parameter free method bases on a trait vector, which is assembled upon the log intensities of 
the selected genes. The classification can be lead back to the k nearest neighbours of already 
classified samples form each sample. The nearest neighbour of the new classified sample is 
chosen via the Euclidean distance between the samples. 
The Euclidean distance is the stereoscopic distance between the k trait vectors of the k 
samples involved in the calculation. Based on this distance to the k neighbours of a new 
classified sample a majority decision is made whether the sample belongs to a group (e.g. 
normal controls) or not. In the application of this algorithm for our data we used a nearest 
centroid prediction, where only two classes of samples are considered. The result of this 
calculation is yes or no (Nigsch et al., 2006). In our case if a sample belongs to a certain 
group or not. The nearest neighbour prediction algorithm, which was applied to create the 
data for figure 27, provided an insight into the statistical relevance of the 8 significant rated 
genes.  
The study group Relapse, which consists of patients with recurrent malign neoplasm, can also 
be distinguished form wild type samples with a reliability of 60%. Including the other study 
groups into this prediction process the prognostic power of our data decreases. We observed a 
likelihood of less than 60 % for patients with a tumor of grade 3 and less than 50% for 
patients with a G1 or G2 tumor to be predicted accurate. 
The study groups Benign and C.I.S. were rated as wild type samples and showed probabilities 
of more than 70% to belong to cancer samples, which is in the range of normal control 
samples. The Benign and C.I.S. samples were rated as cancer samples in another run of this 
prediction method (data not shown) were they also reached a likelihood of between 30% and 
40% to belong to cancer samples.  
For this prediction method it was true that there was highly significant differentiation between 
normal controls and serum of patients with metastasizing tumor. Due to the results of the 
nearest neighbour prediction the performance of the study group “Relapse” has to be 
discussed critically. 
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Fig.27: Nearest neighbour Prediction of all clinical samples applying the 8 significant rated 
genes (table 6). Study groups are indicated below. The bars show the portion of correct 
predicted samples per study group upon nearest centred prediction. The same numbers of 
samples were used as listed in table 5. 
 
 
 
4.3.7. Binary tree Prediction 
 
The binary tree prediction is a method that applies common prediction methods like in this 
case bayesian compound covariant predictor that uses this algorithm not to predict the 
analysed samples into classes, but it attempts to define two or more subclasses. For this 
analyses the samples are divided into several classes for example tumor, normal and benign. 
The algorithm then tries to split the samples into three groups by creation of subgroups that 
show the fewest cross-validated misclassification errors.  
The Bayesian compound covariant predictor method calculates a linear predictor score (LPS) 
for each sample by introducing a scaling factor, which is based on a t-test for the difference 
between the two study groups. In this context the LPS is a linear combination of the median 
signal intensity values and distribution of these within the study groups, which should be 
normal distributed inside the study groups. In this way a mean variance is calculated for these 
normal distributions. This LPS distribution of each subgroup is then used to estimate a 
likelihood of a new sample, to belong to one of the study groups by an application Bayes´ 
rule. This rule allows, simplified expressed, a conversion of conclusions. This method was 
also used as an application of BRB array tools and was first described by (Wright et al., 
2003). 
In our binary tree prediction analysis we created three subgroups, followed by the creation of 
a prediction set and a training set. The prediction set creates a “predictor” by means of the 
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samples in the prediction set and an evaluation is performed with the training set. Therefore 
we divided the samples into a tumor group, a group of normal controls and a group for Benign 
tumors. Then we splitted the samples according to their multiplex-PCR run in the experiment. 
In this way we had a prediction set consisting of study groups of the first two multiplex-PCR 
runs and a training set with the remaining two PCR runs. This analysis was also performed 
the other way around. Using the first two PCRs as “prediction set” we had over 40% of 
misclassified Tumor samples. As we performed the analysis the other way around no creation 
of subgroups was possible. These facts indicated towards a PCR-bias or hybridisation 
artefacts, because the first two PCR-runs were hybridized on one day and the hybridisation of 
the second two PCRs followed on the next day. Therefore we decided to evaluate our analysis 
strategy and then reanalyse the data with a different normalization strategy. 
 
 
4.3.8. Evaluation of micro array analyses  
 
The receiver operator characteristics curve (ROC-curve) is a graphical plot of sensitivity, 
which represents the false negative signals versus specivity that represents the false positives 
signals per sample. If a sample bears neither a false positive signal or a false negative signal it 
is found in the right top corner of the plot, which means 100% sensitivity and specivity. We 
used this analyses method to evaluate the quality and accuracy of our data analyses, because if 
the area under the ROC-curve is 0,5 the data are random distributed, which indicates that the 
analyses was not successful. This is the case if the curve is diagonal through the plot. We 
performed this analysis with various sample collections. The initial approach was to analyse 
only study group M1 versus normal controls, in this case the area under the ROC curve was 
almost one. Subsequently we added all study groups to the analyses. In figure 26 a prediction 
and creation of the ROC-curve was performed analysing the data of the significant rated 
genes of all clinical samples. We observed the most significant decrease of the area under the 
ROC-curve adding the study group “Benign” to the collective of samples although we rated 
them like C.I.S. samples as normal control samples. Therefore we decided to reanalyse our 
data aiming at the detection of markers, which discriminate between study group Benign, and 
cancer samples.  
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Fig. 26: ROC-curve of clinical samples using the 8 genes rated significant. Specifity refers to the false 
positives of each sample; sensitivity to the false negative signals of each sample. 
 
 
4.3.9. Quantile Normalization 
 
The most powerful normalization approach to counter variances between arrays of 
experimental origin is the quantile normalization, but this method has a very strong influence 
on the values of every data point within the array. This normalization algorithm ranks the data 
points of every array. Simplified expressed, the highest value gets “position one” (i.e. quantil 
1) the second “position two” and so on. Then the median value for each data row, which must 
not consist of equal probes (i.e. gene loci), is calculated and inserted in every array at this 
position. This method results in the same distribution of signal intensities on different arrays. 
In this way experimental variances that lead to array specific signal intensity differences have 
no more influence on the data (figure 28). 
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Fig.28: Box plots of normalized signal intensities per slide. Left section after scale normalization (comparable 
to figure 19); right section quantile normalized data. Numbers given below indicate the number of normalized 
arrays. 
 
 
 
4.3.10. Binary tree prediction 
 
We performed a binary tree prediction on the quantil normalized data dividing the samples 
again into three groups namely normal controls, cancer samples and samples of patients with 
a benign neoplasm. A “predictor” was calculated using all in all 21 genes (table 10) among 
them 6 of the 8 significant rated genes discussed in section 4.3.4 and 4.3.5. At this analysis 
approach about 25% of the cancer samples were classified wrong, which was either due to the 
inclusion of the study group Benign as own subgroup into the calculation or the already 
discussed PCR-bias.  
Further we repeated the binary tree prediction as outlined in the 4.3.7 applying the same 
prediction and training set composition, which provided the same result consisting of over 
40% misclassified samples or it was not possible to apply this algorithm if training and test set 
were interchanged. 
1 6 12 18 24 30 36 42 48 54 60 66 72
6
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16
multiplex scale normalised
1 6 12 18 24 30 36 42 48 54 60 66 72
6
8
10
12
14
16
multiplex quantile normalised
Signals per slide, after multiplex normalisation
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Result of binary tree prediction Result of binary tree prediction 
 
Gene name P-Value % CV Gene name P-Value %CV 
  support   support 
 
MYOD1 <0,0005 100% NANOS1 0,004 100% 
 
CTNNB1 <0,0005 100% NCL 0,008 100% 
 
ONECUT2 0,0003 83% CXADR 0,01 100% 
 
SRGN 0,0006 100% GDNF 0,01 100% 
 
NRCAM 0,0007 99% CD24 0,01 100% 
 
CDH1 0,001 73% CLDN1 0,01 100% 
 
TTC3 0,002 93% ZNF502 0,01 93% 
 
DCC 0,002 100% TFF1 0,02 100% 
 
BOLL 0,003 100% ZNF711 0,03 100% 
 
CDH1 0,004 100% PITX2 0,04 59% 
 
TP53 0,004 100%  
 
Tab.10: Output of binary tree prediction. Many gene loci show a significant difference between the study 
groups, but 25% of the cancer samples were misclassified. % CV support indicates the number of samples in % 
at which the application of a cross validation algorithm was possible and therefore reflects the prediction error 
for a test set. 
 
 
4.3.11. Class prediction  
 
As last step of our analyses we performed Class prediction with multiple methods as well as 
binary tree prediction for the PCR runs separately. Applying this strategy we aimed also at the 
discovery of novel marker for a differentiation between Benign neoplasms and cancer 
patients. If a PCR run or prediction strategy is not listed in table 11, the analyses did not 
provide any significant results. Compared to table 6 the P-values are significantly lower, 
which is due to the reduced numbers of samples in the analyses. The division of the samples 
according to their PCR runs was necessary, to guarantee a determination of markers, at which 
a PCR-bias or hybridization artefacts are minimized. Notably, we found two markers that may 
have the potential to discriminate between the serum of normal controls and the study group 
“Benign”. Anyway, both sets of markers (table 6 and table 11) have to be validated via qPCR 
tests before clear conclusions can be made about their diagnostic relevance. 
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Result of multiple prediction analysis 
 
Gene name P-Value method PCR run  discrimination % CV support 
 
TFF 0,02 ClassPred. C+D TU vs Norm 100% 
 
TJP2 0,02 ClassPred. C TU vs Norm 100% 
 
TIMP1 0,019 ClassPred. C TU vs Norm 84% 
 
SMAD3 0,04 ClassPred. C TU vs Norm 47% 
 
TFF 0,006 ClassPred. D TU vs Norm 100% 
 
LZTS1 0,04 ClassPred. D TU vs Norm 23% 
 
IL1B 0.01 ClassPred. D TU vs Norm 100% 
 
TFF 0,006 Bin.TreePred. D TU vs Norm+Ben 100% 
 
TP53 0,046 Bin.TreePred. D TU vs Norm+Ben 100% 
 
CDKN2A 0,009 Bin.TreePred. D Ben vs Norm 33% 
 
C5ORF4 0,027 Bin.TeePred. D Ben vs Norm 61% 
 
 
Tab.11: Output of diverse Prediction methods to reveal serum markers. Method reveres to the applied 
Prediction algorithm. PCR run indicates the used data in the analysis. Discrimination shows division of the 
samples in subgroups within the analysis. % CV support indicates the number of samples in % at which the 
application of a cross validation algorithm was possible and therefore reflects the prediction error for a test set. 
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5. Discussion 
 
An increased level of cell free (cf) DNA in human blood serum was first detected in 
association with systemic lupus in the 1960ies (Tan et al., 1966). These finding fell into 
oblivion for a few decades, but now they are causing a great deal of attention since higher 
amounts of cell free DNA were detected in sera of cancer patients (Shapiro et al., 1983). 
Current research estimates a high diagnostic potential of these free circulating nucleic acids in 
the blood serum. 
In serum, the content of cell free (cf) DNA of healthy adults (Zhong et al., 2007) as well as 
breast cancer patients (Seefeld et al., 2008) is low, but the diagnostic potential of these ng 
amounts is promising (Gahan and Swaminathan, 2008).  
Notably we could affirm the widely discussed increase of cf serum DNA levels of breast 
cancer patient (Kohler et al., 2009) (Van, I et al., 2009). However this elevated DNA amounts 
were observed only in patients with a metastatic disease. Therefore our data rather agree with 
observations of metastatic cancerous diseases (Tokuhisa et al., 2007) than with an increase of 
cf serum DNA of overall malignant cancers (Wu et al., 2002). 
 
Since the technology of qPCR emerged and stood in as gold standard for appointment of 
small DNA amounts, endpoint measurements like Pico Green had become rare in current 
research. We took the decision to adjust the Pico green method and base our work on a simple 
measurement to determine the DNA amounts of the various isolation methods. By this 
approach we measured serum DNA concentrations within the range of 0,72ng – 96,21ng per 
ml. This range is smaller and there are only few outliers compared to recent reported DNA 
concentration measurements by qPCR (Deligezer et al., 2008;Boni et al., 2007;van der Drift 
et al., 2010). Comparing qPCR and Pico green concentration appointments in our study, there 
was a higher correlation of replicate measurements for Pico Green (r = 0,933) than for qPCR, 
where no correlation above 0,84 was achieved (data not shown). A similar satisfactory 
performance and correlation of both methods, like reported by Szpechcinski A. (Szpechcinski 
et al., 2008), could not be accomplished in our experimental setting. 
The decision for an optimized protocol of the Roche High pure template preparation kit was 
evaluated by testing three other DNA purification approaches too. Two bead based methods 
like MBD isolation and ZR Serum DNA kit form Zymo did not provide sufficient amount for 
further DNA processing, although in case of the MBD based approach the methylated fraction 
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of the DNA was already enriched (Wielscher et al., 2010). In case of the membrane based 
isolation strategies the yielded DNA amounts using the optimized Roche protocol was 
significantly higher than using the Quiagen blood midi kit, which is widespread approach in 
current literature (Xue et al., 2009). 
 
To control the sample quality and the entirety of the extracted DNA, we performed a 
multiplex PCR on serum isolates, which led to the detection of 4 amplification products that 
showed product lengths of 124bp up to 315 bp for 4 different gene loci in nearly all analyzed 
samples. These experiments also gave an insight into the DNA integrity by the comparison of 
serum DNA of healthy patients and cancer patients, which did not indicate a decrease of DNA 
integrity. 
The term DNA integrity index was defined in recent reports as the unequal distribution of 
long DNA fragments in relation to shorter ones whereupon the cell free serum or plasma 
DNA of normal controls should show a relative abundance of longer DNA fragments (i.e. 
PCR-products) starting at a size of 300bp. (Umetani et al., 2006;Jiang et al., 2006). By means 
of our observation, performed on 30 serum samples with a malign neoplasm and 24 normal 
controls, we could not support this assumption. Therefore additional qPCR tests on plasma 
isolated DNA were performed where no significant decrease of DNA fragments longer than 
150bp in normal control DNA were detected too (data not shown). So this work emphasizes 
first critically considerations that do not consider an increased DNA integrity index as 
prognostic tool in cancer diagnoses (Schmidt et al., 2008). 
 
Three approaches to achieve a genome wide amplification were tested in this work. On the 
one hand adaptor mediated genome wide amplification systems like APA-PCR and the Whole 
Genome Amplification kit from Sigma-Aldrich, and on the other hand a strand displacement 
dependant approach like the RCA were evaluated. We decided to perform the genome wide 
amplification with the RCA system, because it performed best with the trace input DNA 
amounts isolated from serum. 
The genome wide amplification was performed upon rolling circle amplification (RCA), a 
reliable method with many different applications, ranging from the amplification of vectors 
for cloning to template dependant amplification system in an isothermal reaction (Lizardi et 
al., 1998). In this study, however, we aimed, using the “phi29” Polymerase for amplification 
of methylated DNA fragments, at a establishing of the multiplex-PCR mediated detection on 
our target arrays. Methylation sensitive restriction digestion guaranteed the enrichment of the 
methylated DNA fraction, because only methylated DNA fragments were left behind, which 
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not got digested and therefore were amplified by the “phi29” Polymerase. In this way DNA 
amounts in range of at least 10µg were produced out of a minimal sample input (10ng). We 
found that the genome wide amplification reaction is extremely dependant on the input DNA 
amount and the sample quality (Figure 15). The analyses of the gel images after RCA and the 
second control PCR (Figure 17) lead to the conclusion that the DNA recovery in this assay 
averaged out at 70%. We found a slightly higher number of complete RCA reactions as 
observed by Wang G. and colleagues (Wang et al., 2004), who also performed RCA reaction 
on serum isolates. This might be due to different reaction conditions. Other voices, on the 
contrary, claim to obtain a DNA profile after rolling circle amplification with a similarity of 
80% (complete RCA reactions) and more to the unamplified serum or plasma sample via SNP 
or micro satellite DNA analyses. (Nakamoto et al., 2008;Croft, Jr. et al., 2008). Further Croft 
D.T.jr. and colleagues achieved to isolate on average 366ng +/-27ng out of 200µl human 
blood plasma, a DNA amount that was never observed again in corresponding literature 
before or after this publication, might be due to remaining cells, which were avoided in our 
setting. 
The detection of differential methylated DNA fragments was guaranteed via multiplex PCR 
followed by hybridization on a target array. After confirmation of an accurate performance of 
the detection system (section 4.3.2 and 4.3.3) we started the micro array analysis. 
In our micro array analyses, we used class comparison methods to distinguish between two 
sample groups, which lead to a first determination of significant genes and creation of 
overview result tables. These tests provided first results that lead to a discrimination between 
the normal control group and patients with a metastasizing tumor with high level of 
significance. In further tests we detected that significant genes might be also due to an 
influence of the experimental setting. Therefore the accuracy of this selection of genes has to 
be questioned critically, but a qPCR-based evaluation of these possible markers will solve this 
question. 
Additional analyses with reduced sample numbers were performed, in way that an influence 
of experimental variances is excluded, which lead to the discovery of another 10 possible 
methylation markers to distinguish between patients with malign neoplasms and normal 
controls. In this case the level of significance was lower (P< 0,05). 
To give an overview of the biological meaning and possible clinical potential of the revealed 
methylation markers, we selected a few of them and discussed their biological function and 
the influence of their methylation on the affected cell in detail. 
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One example for a methylation marker  we found in our study is the aberrant methylation of 
the promoter region of TP53 better known as p53, which is hyper-methylated in cancer. The 
gene product of p53 is a DNA binding protein that acts as transcription factor, which inhibits 
expression of growth and invasion factors and therefore is a typical tumor suppressor gene. In 
healthy cells p53 is expressed at a low level and leads via induction of several genes to cell 
cycle arrest or apoptosis as response to cellular stress (Amaral et al., 2010). Besides germ line 
mutation (Li-Fraumeni syndrome, section 1.2.3) also aberrant methylation of the promoter 
region was observed in many cancer types (Patra, 2008). Our study confirms the finding of 
recent research reports that p53 is a possible methylation marker prevailing in serum of cancer 
patients (Fleischhacker and Schmidt, 2007). 
 
The methylation status of the TMEFF2 gene in breast cancer was already described by Suzuki 
M. and co-workers (Suzuki et al., 2005). They compared 4 normal cell lines where the 
TMEFF2 gene product was expressed in all 4 of them and methylated in none, to 10-breast 
cancer cell lines were the gene was expressed in 50% of the cell lines and methylated in the 
other 50% (Suzuki et al., 2005). Further they observed a promoter hypermethylation of the 
gene in 35% of clinical samples, dependent on TNM staging of the tumor, where upon the 
frequency of the methylated tumors increased in accordance to higher TNM stages (Suzuki et 
al., 2005). Our data complete these observations, because we detected TMEFF2 methylation 
in 80% of the tested metastasizing serum tumor samples. TMEFF2 methylation frequency in 
samples of less invasive neoplasm was 60% in the study group relapse, and 20% at G2 and 
G3. The gene product of TMEFF2 acts as epidermal growth factor and its aberrant promoter 
methylation was verified in colorectal tumors, gastric adenocarcinomas and other cancer types 
(Shibata et al., 2002), where this locus was methylated on average in 80% of the tested 
sample material.  
 
The situation at the analyses of KLF4 was the other way round. The KLF4 promoter region 
was methylated in normal controls and an absence of the KLF4 methylation in the study 
groups M1 and Relapse. KLF4 denotes the Kruppel-like factor 4, which was identified as 
tumor suppressor gene in colorectal cancer (Zhao et al., 2004). KLF4 is a zinc-finger protein 
that acts as repressor or activator of transcription and its over-expression leads to an arrest of 
the cell cycle at the stage of G1/S1. This model was confirmed by several in vitro experiments 
and gene knockouts, (Ghaleb et al., 2005) but the authors also reported increased levels of 
KLF4 mRNA detected in breast cancer and squamous cell carcinoma. These findings were 
due to a change of the biological behaviour of KLF4 in conjunction with different tumor 
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models. Our study may contribute to the elucidation of the reason for this, till now, not well-
understood process, because we showed that the KLF4 methylation is decreased in breast 
cancer stages M1 and relapse, which would explain an increase of expression found by other 
work (Ghaleb et al., 2005). 
 
The DCC gene product is well described as a transmembrane protein called netrin 1 receptor 
that induces apoptosis of the cell in presence of its ligand nectin 1. Therefore it was classified 
as tumor suppressor gene, since it was found to be deleted in colorectal cancer (DCC) for the 
first time in 1990. The methylation of this locus and the successional loss of gene expression 
were shown for a handful of cancer types like gastric, head and neck, oesophageal squamous 
cell carcinoma and breast cancer (Park et al., 2008). In our study we observed 40.7% 
methylated promoter regions of DCC including all the study groups with a malign neoplasm 
M1, Relapse and G1-G3, which agreed with previous findings of the methylation status of 
DCC in breast cancer (Miyamoto et al., 2005). 
 
Claudins have been found a potential diagnostic marker for gynaecological, lung, pancreas 
and other cancers. There is only little published about CLDN1 methylation and for CLDN3 
and CLDN5. Some reports are suggesting that CLND3 and CLDN5 are aberrantly methylated 
in a few cancer types (Sato et al., 2003). For all three genes, precise expression data of each 
gene in diverse cancers, including breast cancer, are available. In the case of the gene 
claudin1 (CLDN1), a trans membrane protein that forms tight junctions in epithelial cells, the 
down regulation was associated with carcinogenesis in breast cancer (Morohashi et al., 2007). 
A coherence of down-regulated CLDN1 gene expression and the recurrence of breast cancer 
as well as an increased loss of expression in metastasizing tumors could be demonstrated. 
Mutation analysis of this gene did not provide any significant results in connection to its 
behaviour in breast cancer (Kramer et al., 2000). Our data on the one hand clarify the 
mutation analysis study, because our data strongly indicate that the silencing of CLDN1 might 
be promoter-methylation mediated, and on the other hand, support the a decrease in 
expression data of CLDN1 related to breast cancer. We detected a methylation frequency of 
100% from patients with metastasizing disease and a frequency of 83% for patients with 
recurrent breast cancer (study group Relapse). Furthermore the prevalence of the methylated 
promoter region of CLDN1 decreased rapidly to 28% in samples with less pronounced cancer 
phenotypes (i.e. study group G1-G3). A follow-up study to access whether the cancer of these 
28% of patients developed a metastasizing stage or was recurrent would be interesting.  
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Another methylation marker with high-predicted statistical significance was the promoter 
region of BOLL, a member of the DAZ-gene family, which plays an important role in germ 
cell development. The loss of a functioning gene product of BOLL was brought into 
connection with infertility of both sexes, because this translational regulator promotes the 
formation of haploid gametes (Kee et al., 2009). Apart from embryonic stem cell researchers, 
this gene attracted the attention of Shames DS (Shames et al., 2006), who observed a four 
time higher expression of the BOLL gene, upon the induction of expression of methylated 
genes by 5-aza-2´-deoxycytidine treatment, compared to the results of cell lines derived from 
normal tissue that were treated the same way. The aberrant methylation of BOLL in breast 
cancer is indeed difficult to interpret, because this gene is predominantly expressed in germ 
cells (Yen, 2004). In this case we might have discovered a possible new marker for breast 
cancer, but to determine a functional role for this aberrant methylation, further tests would be 
necessary. A few assumptions in current literature could be applied for this finding, like a 
silencing process of genes that are not crucial for differentiation into tumor cells 
(Widschwendter et al., 2007). Here a repression of the polycomb group proteins (Lee et al., 
2006), factors that regulate developmental genes upon trimethylation of histone H3 in 
embryonic stem cells is suggested, which would lead to an aberrant methylation pattern of 
this hypothesized cancer precursor cells. 
Each gene discussed here would have a great potential to serve diagnostic marker or 
contribute to the understanding of malign neoplasms, but they have to undergo a precise 
evaluation before a further investigations would be meaningful. However, we developed a 
reproducible working protocol suitable for genome wide methylation screening of cell free 
serum DNA. 
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6. Conclusion 
 
1. We established a serum DNA isolation protocol that enabled us to purify high DNA 
amounts in reproduce able manner from 1ml of patient serum. The application of this 
protocol resulted in a detection of significant increased DNA amounts in serum of 
breast cancer patients with a metastasizing tumor. 
2. We successfully applied a methylated DNA enrichment procedure for the generation 
of satisfying DNA amounts out of limited DNA samples. 
3. The utilization of the targeted “CpG-360” test elucidated 8 candidate marker genes, 
which might have the potential to discriminate between patients with a metastasising 
breast cancer and normal controls. Although our analysis also turned out that these 
markers could have been influenced by an experimental bias. 
4. Further we could define 10 possible methylation markers, at which, due to our 
analysis approach, an influence of experimental variances is excluded.  
5. Possibly this work is another step towards the development of a minimal invasive 
breast cancer test. Further qPCR tests could elucidate if these biomarkers, revealed 
here, have the potential to severe as serum methylation markers for breast cancer. 
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